TW202118770A - 異質雙環肽複合物 - Google Patents
異質雙環肽複合物 Download PDFInfo
- Publication number
- TW202118770A TW202118770A TW109124761A TW109124761A TW202118770A TW 202118770 A TW202118770 A TW 202118770A TW 109124761 A TW109124761 A TW 109124761A TW 109124761 A TW109124761 A TW 109124761A TW 202118770 A TW202118770 A TW 202118770A
- Authority
- TW
- Taiwan
- Prior art keywords
- peptide
- bcy11863
- acid
- nectin
- tumor
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 156
- 125000002619 bicyclic group Chemical group 0.000 title claims abstract description 33
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 82
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims abstract description 74
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims abstract description 70
- 101710043865 Nectin-4 Proteins 0.000 claims abstract description 65
- 102100035486 Nectin-4 Human genes 0.000 claims abstract description 65
- 239000003446 ligand Substances 0.000 claims abstract description 56
- 201000011510 cancer Diseases 0.000 claims abstract description 19
- 238000011282 treatment Methods 0.000 claims description 35
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 239000002253 acid Substances 0.000 claims description 21
- 239000002062 molecular scaffold Substances 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 15
- 230000036470 plasma concentration Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- WDEYOYQVZPSNFR-UHFFFAOYSA-N 3-[2-[2-[2-[bis[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethyl]amino]ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound OC(=O)CCOCCOCCOCCN(CCOCCOCCOCCN=[N+]=[N-])CCOCCOCCOCCN=[N+]=[N-] WDEYOYQVZPSNFR-UHFFFAOYSA-N 0.000 claims description 11
- 229920001184 polypeptide Polymers 0.000 claims description 11
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- FYBFGAFWCBMEDG-UHFFFAOYSA-N 1-[3,5-di(prop-2-enoyl)-1,3,5-triazinan-1-yl]prop-2-en-1-one Chemical compound C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)C=C)C1 FYBFGAFWCBMEDG-UHFFFAOYSA-N 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- LPBSHGLDBQBSPI-YFKPBYRVSA-N (2s)-2-amino-4,4-dimethylpentanoic acid Chemical compound CC(C)(C)C[C@H](N)C(O)=O LPBSHGLDBQBSPI-YFKPBYRVSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 claims description 3
- 230000001629 suppression Effects 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 35
- 239000000203 mixture Substances 0.000 description 32
- -1 (3-(bromomethyl)benzene) (tris-(bromomethyl)benzene) Chemical compound 0.000 description 29
- 125000000539 amino acid group Chemical group 0.000 description 25
- 239000011541 reaction mixture Substances 0.000 description 23
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 17
- 230000000259 anti-tumor effect Effects 0.000 description 17
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 238000007912 intraperitoneal administration Methods 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 238000002953 preparative HPLC Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 210000004881 tumor cell Anatomy 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000008901 benefit Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- 238000011191 terminal modification Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 9
- 238000009826 distribution Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- VAKXPQHQQNOUEZ-UHFFFAOYSA-N 3-[4-[[bis[[1-(3-hydroxypropyl)triazol-4-yl]methyl]amino]methyl]triazol-1-yl]propan-1-ol Chemical compound N1=NN(CCCO)C=C1CN(CC=1N=NN(CCCO)C=1)CC1=CN(CCCO)N=N1 VAKXPQHQQNOUEZ-UHFFFAOYSA-N 0.000 description 7
- 102000035195 Peptidases Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000004614 tumor growth Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 150000008574 D-amino acids Chemical class 0.000 description 6
- 108060005251 Nectin Proteins 0.000 description 6
- 102000002356 Nectin Human genes 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000006054 immunological memory Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012299 nitrogen atmosphere Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 108010069514 Cyclic Peptides Proteins 0.000 description 5
- 102000001189 Cyclic Peptides Human genes 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000000562 conjugate Substances 0.000 description 5
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 4
- 101001023705 Homo sapiens Nectin-4 Proteins 0.000 description 4
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 4
- 150000008575 L-amino acids Chemical class 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000004743 Polypropylene Substances 0.000 description 4
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 239000012496 blank sample Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 102000050327 human TNFRSF9 Human genes 0.000 description 4
- 102000043460 human nectin4 Human genes 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229920001155 polypropylene Polymers 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 241000233805 Phoenix Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- 206010042971 T-cell lymphoma Diseases 0.000 description 3
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 230000006023 anti-tumor response Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 201000009277 hairy cell leukemia Diseases 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229940032330 sulfuric acid Drugs 0.000 description 3
- 239000013595 supernatant sample Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 0 *CCOCCOCCOCCN(CCOCCOCCOCC*)CCOCCOCCOCCC(O)=O Chemical compound *CCOCCOCCOCCN(CCOCCOCCOCC*)CCOCCOCCOCCC(O)=O 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 108010000239 Aequorin Proteins 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101001023706 Mus musculus Nectin-4 Proteins 0.000 description 2
- 102000056189 Neutrophil collagenases Human genes 0.000 description 2
- 108030001564 Neutrophil collagenases Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 230000008484 agonism Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001345 alkine derivatives Chemical class 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
- 238000011198 co-culture assay Methods 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007306 functionalization reaction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- 235000012208 gluconic acid Nutrition 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 150000002678 macrocyclic compounds Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940074355 nitric acid Drugs 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N para-acetamidobenzoic acid Natural products CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000012877 positron emission topography Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000003752 saphenous vein Anatomy 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 206010042863 synovial sarcoma Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 2
- WOLXSUFTTIRQOU-BVCQTOFBSA-N (2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)ON1C(=O)CCC1=O WOLXSUFTTIRQOU-BVCQTOFBSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- QGKMIGUHVLGJBR-UHFFFAOYSA-M (4z)-1-(3-methylbutyl)-4-[[1-(3-methylbutyl)quinolin-1-ium-4-yl]methylidene]quinoline;iodide Chemical compound [I-].C12=CC=CC=C2N(CCC(C)C)C=CC1=CC1=CC=[N+](CCC(C)C)C2=CC=CC=C12 QGKMIGUHVLGJBR-UHFFFAOYSA-M 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229930007886 (R)-camphor Natural products 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FABVRSFEBCDJLC-UHFFFAOYSA-N 1,2,3-tris(bromomethyl)benzene Chemical compound BrCC1=CC=CC(CBr)=C1CBr FABVRSFEBCDJLC-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 229940116741 CD137 agonist Drugs 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 208000032027 Essential Thrombocythemia Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 208000006937 Hydatidiform mole Diseases 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 206010023347 Keratoacanthoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 208000037196 Medullary thyroid carcinoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010028767 Nasal sinus cancer Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000003937 Paranasal Sinus Neoplasms Diseases 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 208000008601 Polycythemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 206010044002 Tonsil cancer Diseases 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- UGJQDKYTAYNNBH-UHFFFAOYSA-N amino cyclopropanecarboxylate Chemical compound NOC(=O)C1CC1 UGJQDKYTAYNNBH-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000007455 central nervous system cancer Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000007821 culture assay Methods 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-O cysteaminium Chemical compound [NH3+]CCS UFULAYFCSOUIOV-UHFFFAOYSA-O 0.000 description 1
- 238000003568 cytokine secretion assay Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000009033 hematopoietic malignancy Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 229960002050 hydrofluoric acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000003468 luciferase reporter gene assay Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- LGAILEFNHXWAJP-BMEPFDOTSA-N macrocycle Chemical group N([C@H]1[C@@H](C)CC)C(=O)C(N=2)=CSC=2CNC(=O)C(=C(O2)C)N=C2[C@H]([C@@H](C)CC)NC(=O)C2=CSC1=N2 LGAILEFNHXWAJP-BMEPFDOTSA-N 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 206010028537 myelofibrosis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 230000002632 myometrial effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N n-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 201000007052 paranasal sinus cancer Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000003476 primary myelofibrosis Diseases 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000012070 reactive reagent Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108010037022 subtiligase Proteins 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013818 thyroid gland medullary carcinoma Diseases 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 208000029387 trophoblastic neoplasm Diseases 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/641—Branched, dendritic or hypercomb peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明係關於一種異質雙環肽複合物,包括一第一胜肽配體,與Nectin-4結合,透過一連接胜肽共軛至兩個第二胜肽配體,該第二胜肽配體與CD137結合。本發明還關於該異質雙環肽複合物在預防、抑制或治療癌症中的用途。
Description
本發明係關於一種異質雙環肽複合物,包括一第一胜肽配體,與Nectin-4結合,透過一連接胜肽共軛至兩個第二胜肽配體,該第二胜肽配體與CD137結合。本發明還關於該異質雙環肽複合物在預防、抑制或治療癌症中的用途。
環肽可以以高親和力及標靶特異性與蛋白質標靶結合,因此對於治療學的發展是具有吸引力的分子類別。實際上,臨床上已經成功使用了多種環肽,例如抗菌胜肽萬古黴素(vancomycin)、免疫抑制劑藥物環孢素(immunosuppressant drug cyclosporine)或抗癌藥物奧曲肽(octreotide)(Driggers等(2008),Nat Rev Drug Discov 7(7),608-24)。良好的結合特性是由於胜肽與標靶之間形成的相對較大的相互作用表面及環狀結構的構造靈活性(conformational flexibility)降低。通常,大環(macrocycle)與數百平方埃的表面結合,例如環肽CXCR4拮抗劑CVX15(400 Å2,Wu等(2007),Science 330,1066-71)、具有與整合素αVb3結合的Arg-Gly-Asp基序的環肽(355 Å2)(Xiong等,(2002),Science 296(5565),151-5)或與尿激酶型纖維蛋白溶酶原活
化物(plasminogen activator)結合的環肽抑制劑upain-1(603 Å2,Zhao等(2007),J Struct Biol 160(1),1-10)。
由於其環狀構型,胜肽大環的柔韌性比線性胜肽差,導致與標靶結合後熵損失較小,並導致更高的結合親和力。與線性胜肽相比,降低的柔韌性還導致鎖定標靶專一性結構、增加結合專一性。這種作用已透過基質金屬蛋白酶8(MMP-8)的有效及選擇性抑制劑得到了例證,該抑制劑在開環時失去了對其他MMP的選擇性(Cherney等人(1998年),J Med Chem 41(11),1749-51)。透過大環化獲得的有利的結合特性在具有多於一個肽環的多環肽中更為顯著,例如在萬古黴素(vancomycin)、乳酸鏈球菌素(nisin)及放線菌黴素(actinomycin)中。
不同的研究團隊先前已將具有半胱胺酸殘基的多胜肽束縛到合成分子結構上(Kemp及McNamara(1985),J.Org.Chem;Timmerman等(2005),ChemBioChem)。Meloen及其同事已使用三(溴甲基)苯及相關分子將多個胜肽環快速且定量地環化到合成支架上,用於蛋白質表面的結構模擬(Timmerman等(2005),ChemBioChem)。產生候選藥物化合物的方法,其中該化合物是透過將含多胜肽的半胱胺酸連接到分子支架上而產生的,該分子支架例如為揭示於WO 2019/122860及WO 2019/122863中的1,1’,1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA)。
已經開發了基於噬菌體顯示的組合方法來產生及篩選針對感興趣標靶的雙環胜肽的大型資料庫(Heinis等(2009),Nat Chem Biol 5(7),502-7及WO 2009/098450)。簡而言之,在噬菌體上顯示包含三個半胱胺酸殘基及兩個區域的六個隨機胺基酸(Cys-(Xaa)6-Cys-(Xaa)6-Cys)的線性胜肽的組合資料
庫,並透過將半胱胺酸側鏈共價連接至小分子(3-(溴甲基)苯)(tris-(bromomethyl)benzene)而環化。
根據本發明的第一態樣,提供一種異質雙環肽複合物,包括:
(a)一第一胜肽配體,與Nectin-4結合,且該第一胜肽配體具有序列CiP[1Nal][dD]CiiM[HArg]DWSTP[HyP]WCiii(SEQ ID NO:1;BCY8116);透過一N-(酸-PEG3)-N-雙(PEG3-疊氮化物)(N-(acid-PEG3)-N-bis(PEG3-azide))連接胜肽共軛至
(b)兩個第二胜肽配體,與CD137結合,該第二胜肽配體具有序列Ac-Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii-A(SEQ ID NO:2;BCY8928);
其中每個該胜肽配體包括一多肽,該多肽包括被兩個循環序列隔開的三個反應性半胱胺酸基團(Ci、Cii及Ciii),及一分子支架,該分子支架為1,1’,1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(1,1’,1”-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one)(TATA),且該分子支架與該多肽的該反應性半胱胺酸基團形成共價鍵,從而在該分子支架上形成兩個多肽環;
其中Ac代表乙醯基、HArg代表高精胺酸、HyP代表反式-4-羥基-L-脯胺酸、1Nal代表1-萘丙胺酸、tBuAla代表叔丁基丙胺酸、PYA代表4-戊炔酸及Nle代表正白胺酸。
根據本發明的再一態樣,提供一種醫藥組合物,包括如本文所定義的異質雙環肽複合物與一或多種藥學上可接受的賦形劑合併使用。
根據本發明的再一態樣,提供如本文所定義的用於預防、抑制或治療癌症的異質雙環肽複合物之用途。
圖1:(A)於存在Nectin-4表達的H292細胞的情況下,在Promega CD137螢光素酶報導基因分析(luciferase reporter assay)中對Nectin-4/CD137異質雙環肽複合物的分析。BCY11617是異質雙環肽複合物,以與BCY11863相同的親和力結合Nectin-4,但不結合CD137。(B)在Promega CD137螢光素酶報導基因分析中,BCY11863的總EC50(nM)與內源性Nectin-4表達或經工程改造Nectin-4過表達的不同細胞株共培養。
圖2:Nectin-4/CD137異質雙環肽複合物在PBMC-4T1共培養試驗中誘導IFN-γ(圖2A)及IL-2(圖2B)細胞因子(cytokine)分泌。經工程改造過的4T1細胞以表達Nectin-4。BCY11617是異質雙環肽複合物,以與BCY11863相同的親和力結合Nectin-4,但不結合CD137。圖2C表示在具有多重人類PBMC供體及腫瘤細胞株的細胞因子分泌測定中,BCY11863的總EC50(nM)。
圖3:異質雙環肽複合物BCY11863在SD大鼠及馬來猴(cynomolgus monkey,cyno)中靜脈注射劑量分別為2mg/kg(n=3)及1mg/kg(n=2)的藥物動力學。
圖4:BCY11863在同系(syngeneic)小鼠中Nectin-4過表達的MC38腫瘤模型(MC38#13)中的抗腫瘤活性。BCY11863治療期間及之後的腫瘤體積。括號中
標出了D69上完全緩解(complete responder,CR)小鼠的數量。QD:每日劑量;Q3D:每三天給藥一次;ip:腹膜內給藥。
圖5:BCY11863治療導致對Nectin-4過表達的MC38腫瘤細胞(MC38#13)的免疫性記憶。初次接種C57BL/6J-hCD137小鼠或對BCY11863具有完全緩解(complete response,CR)的小鼠接種後,顯示的腫瘤體積。須注意的是,在觀察期結束時(22天),沒有一隻CR小鼠出現腫瘤。
圖6:BCY11863在同系小鼠Nectin-4過表達的CT26腫瘤模型(CT26#7)中顯示出抗腫瘤活性。BCY11863治療期間的腫瘤體積。Q3D:每三天給藥一次;ip:腹膜內給藥。
圖7:在BCY11863的最後一次(第6次)Q3D劑量後1小時,CT26#7腫瘤組織中的總T細胞及CD8+T細胞增加。在BCY11863的最後一次Q3D劑量後1小時,分析在CT26#7腫瘤組織中的(A)總T細胞、CD8+T細胞、CD4+T細胞、Treg及(B)CD8+T細胞/Treg比。
圖8:在單次靜脈內(iv)給藥5mg/kg的BCY11863後,BCY11863在CT26#7同系腫瘤動物的血漿及腫瘤組織中的藥物動力學分佈。
圖9:在CD-1小鼠(n=3)中腹膜內劑量為15mg/kg時,BCY11863的血漿濃度-時間曲線和BCY11863的終末血漿半衰期(terminal plasma half life)。
圖10:BCY11863與固定化的(A)Nectin-4及(B)CD137的表面電漿共振(SPR)結合研究。雙重結合SPR分析將(C)CD137及(D)Nectin-4固定在SPR晶片上,然後捕獲BCY11863。透過使可溶性受體以不同濃度流過晶片,可以測量結合的BCY11863對可溶性人類Nectin-4(C)或CD137(D)的親和力。(E)
固定在鏈黴親和素SPR晶片上的BCY13582(生物素化的BCY11863)與可溶性人CD137的結合。
圖11:Retrogenix的細胞微陣列技術用於探索BCY13582(生物素化的BCY11863)的非專一性脫靶交互作用。此處顯示的篩選數據顯示,添加到表達11種不同蛋白質的微陣列玻片上的1μM BCY13582僅與CD137及Nectin-4結合(使用AlexaFluor647標記的鏈黴親和素(streptavidin)檢測)。與BCY11863培養後,結合訊號發生位移。
圖12:在huCD137 C57Bl/6小鼠中MC38#13腫瘤的腫瘤生長曲線證明了在不同劑量和劑量間隔後BCY11863的抗腫瘤活性。括號中表示治療開始後第15天的完全緩解動物(CR;無明顯腫瘤)的數量。
圖13:在huCD137 C57Bl/6小鼠中MC38#13腫瘤(n=6/組(cohort))的腫瘤生長曲線(平均值±SEM)證明了BCY11863在不同劑量及劑量方案下的抗腫瘤活性。括號中表示治療開始後第52天的完全緩解動物(CR;無明顯腫瘤)的數量。
(A)接受媒介物或每週BCY11863總劑量3mg/kg的組。(B)接受媒介物或每週BCY11863總劑量為10mg/kg的組。(C)接受媒介物或每週BCY11863總劑量為30mg/kg的組。
圖14:異質雙環肽複合物BCY11863在SD大鼠中以100mg/kg(n=3)靜脈注射的藥物動力學,並測量血漿中BCY11863及潛在代謝物BCY15155以及BCY14602的濃度。
根據本發明的第一態樣,提供了一種異質雙環肽複合物,包括:
(a)一第一胜肽配體,與Nectin-4結合,且該第一胜肽配體具有序列CiP[1Nal][dD]CiiM[HArg]DWSTP[HyP]WCiii(SEQ ID NO:1;BCY8116);透過一N-(酸-PEG3)-N-雙(PEG3-疊氮化物)(N-(acid-PEG3)-N-bis(PEG3-azide))連接胜肽共軛至
(b)兩個第二胜肽配體,與CD137結合,該第二胜肽配體具有序列Ac-Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii-A(SEQ ID NO:2;BCY8928);
其中每個該胜肽配體包括一多肽,該多肽包括被兩個循環序列隔開的三個反應性半胱胺酸基團(Ci、Cii及Ciii),及一分子支架,該分子支架為1,1’,1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(1,1’,1”-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one)(TATA),且該分子支架與該多肽的該反應性半胱胺酸基團形成共價鍵,從而在該分子支架上形成兩個多肽環;
其中Ac代表乙醯基、HArg代表高精胺酸、HyP代表反式-4-羥基-L-脯胺酸、1Nal代表1-萘丙胺酸、tBuAla代表叔丁基丙胺酸、PYA代表4-戊炔酸及Nle代表正白胺酸。
本文提及的N-(酸-PEG3)-N-雙(PEG3-疊氮化物)(N-(acid-PEG3)-N-bis(PEG3-azide))連接胜肽包括:
N-(酸-PEG3)-N-雙(PEG3-疊氮化物)。
於一實施例中,異質雙環肽複合物為BCY11863:
BCY11863的完整詳細訊息如下表A所示:
本文的數據顯示於圖1及表1中,其表明BCY11863在CD137報導基因分析(reporter assay)中顯示出強的CD137活性。此外,本文的數據顯示於圖2及表2中,其表明BCY11863在具有多重腫瘤細胞株及人類PBMC供體的PBMC共培養測定中誘導穩健的IL-2及IFN-γ細胞激素分泌。再者,本文的數據顯示於圖3及表5,其表明BCY11863表現出優異的PK曲線,在SD大鼠中的終末半衰期(terminal half-life)為4.1小時,在馬來猴中的終末半衰期為5.3小時。圖10及圖11以及方法第11部分及第12部分顯示的數據證明BCY11863對標靶Nectin-4及CD137的結合及出色的選擇性。圖4及圖5證明了BCY11863在MC38#13同系小鼠中的深層抗腫瘤活性以及在BCY11863治療後免疫性記憶的形成。圖6及圖7證明了BCY11863在CT26#7同系模型中的抗腫瘤活性,並相應地將細胞毒性T細胞浸潤到腫瘤中。圖12及圖13清楚地證明BCY11863不必維持可測量的血漿濃度,因為在一周的0、24小時內以1.5mg/kg BIW及5mg/kg的劑量給藥可產生穩健的抗腫瘤活性。
本文參考了BCY11863的某些類似物(即改質衍生物)及代謝物,它們各自構成本發明的其他方面,並彙總在下表B中:
其中BCY14601代表具有TATA作為分子支架的具有Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii-A(SEQ ID NO:3)的序列的雙環肽配體;
以及其中BCY13389代表具有TATA作為分子支架的具有[Ac]Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii-K(SEQ ID NO:4)的序列的雙環肽配體。
除非另有定義,否則本文所用的所有技術及科學術語具有與本領域普通技術人員通常理解的相同含義,諸如胜肽化學、細胞培養及噬菌體顯示、核酸化學及生物化學領域。將標準技術用於分子生物學、遺傳及生化方法(參見Sambrook等,Molecular Cloning:A Laboratory Manual,3rd ed.,2001,Cold Spring Harbor Laboratory Press,Cold Spring Harbor,NY;Ausubel等,Short Protocols in Molecular Biology(1994)4th ed.,John Wiley & Sons,Inc.),在此引用作為參考文件。
命名法
編號
當提及本發明化合物中的胺基酸殘基位置時,由於其不變,因此從編號中省略了半胱胺酸殘基(Ci、Cii及Ciii),因此,將SEQ ID NO:1中胺基酸殘基的編號如下所示:
Ci-HyP1-L2-V3-N4-P5-L6-Cii-L7-E8-P9-d1Nal10-W11-T12-Ciii(SEQ ID NO:1)。
為了此描述的目的,雙環肽用1,1’,1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(TATA)環化,並取得三取代結構。TATA的環化反應發生在Ci、Cii及Ciii上。
分子形式
將雙環核心序列的N-或C-末端延伸區添加到序列的左側或右側,並以連字符分隔。例如,N-末端βAla-Sar10-Ala尾巴將表示為:
βAla-Sar10-A-(SEQ ID NO:X)。
反向胜肽序列
根據Nair等人(2003)J Immunol 170(3),1362-1373中的揭示,設想本文揭示的胜肽序列也將以其反向形式找到效用。例如,序列被顛倒(即N-末端變為C-末端,反之亦然),並且其立體化學同樣也被顛倒(即D-胺基酸變為L-胺基酸,反之亦然)。為了避免疑問,除非另有說明,否則將胺基酸全名或胺基酸單個或三個字母表示為L-胺基酸。如果打算將此類胺基酸表示為D-胺基酸,則該胺基酸將在方括號內以小寫字母d開頭,例如[dA]、[dD]、[dE]、[dK]、[d1Nal]、[dNle]等。
胜肽配體的優勢
本發明的某些異質雙環肽複合物具有許多有利的性質,使它們被認為是適合於注射、吸入、鼻、眼、口服或局部給藥的類藥物分子。這些有利的性質包含:
-物種交叉反應。這是臨床前藥物效力學及藥物動力學評估的典型要求;
-蛋白酶穩定性。異質雙環肽複合物應理想地表現出對血漿蛋白酶、上皮(“‘膜錨定”(membrane-anchored))蛋白酶、胃及腸蛋白酶、肺表面蛋白酶、細胞內蛋白酶等的穩定性。應當在不同物種之間保持蛋白酶的穩定性,從而可以在動物模型中開發出異質雙環肽先導候選物,並可以對人類充滿信心地進行給藥;
-理想的溶解度曲線。這是帶電荷的及親水的相對於疏水的殘基及分子內/分子間H鍵的比例的函數,這對於配製及吸收目的是很重要的;
-選擇性。本發明的某些異質雙環肽複合物表現出對其他標靶的良好選擇性。
-循環中最佳的血漿半衰期。根據臨床適應症及治療方案,可能需要開發一種異質雙環肽複合物以在急性疾病管理環境中用於短時間暴露,或開發出一種
在循環中具有增強的滯留性的異質雙環肽複合物,因此最適合用於管理更多的慢性疾病狀態。導致理想的血漿半衰期的其他因素是為獲得最大的治療效率所需要的持續暴露與由於試劑的持續暴露而伴隨的毒理學相對。
重要的是,本文提供的數據,其中當本發明的異質雙環肽複合物以不維持血漿濃度高於該化合物的體外EC50的頻率給藥時表現出抗腫瘤功效。這與CD137促效作用(agonism)或雙特異性CD137促效作用的更大的重組生物方法(即基於抗體的方法)相反(Segal等人,Clin Cancer Res.,23(8):1929-1936(2017),Claus等人,Sci Trans Med.,11(496):eaav5989,1-12(2019),Hinner等人,Clin Cancer Res.,25(19):5878-5889(2019))。不受理論的束縛,認為該觀察的原因是由於異質雙環肽複合物具有相對較低的分子量(通常<15kDa),它們是完全合成的,且它們是CD137的腫瘤標靶促效劑。如此一來,它們具有相對短的血漿半衰期,但是具有良好的腫瘤滲透性及滯留性。本文提供的數據完全支持這些優勢。例如,每天或每3天證明具有人源化CD137的小鼠在同系囓齒動物模型中的抗腫瘤功效。此外,腹膜內的藥物動力學數據顯示血漿半衰期小於3小時,這可預示複合物的循環濃度在兩次給藥之間將始終低於體外EC50。再者,與血漿量相比,腫瘤藥物動力學數據顯示在腫瘤組織中異質雙環肽複合物的量可能更高且更持久。
應當理解的是,這種觀察形成本發明重要的另一態樣。因此,根據本發明的另一態樣,提供了一種治療癌症的方法,包括以一劑量頻率(dosage frequency)給予如本文所述的異質雙環肽複合物,而該劑量頻率為以不維持該複合物的血漿濃度高於該複合物的體外EC50的劑量頻率。
-免疫記憶。癌細胞結合雙環肽配體與免疫細胞結合雙環肽配體的耦合coupling)提供了免疫記憶的協同優勢。本文提供的數據表明,本發明的異質雙環雙環肽複合物不僅根除了腫瘤,而且在再次施用致瘤劑後,接種的完全緩解小鼠均未出現腫瘤(參見圖5)。這表明用本發明選定的異質雙環肽複合物治療已經在完全緩解小鼠中誘導了免疫性記憶。這具有顯著的臨床優勢,以防止該腫瘤一旦被初步控制及根除就復發。
胜肽配體
如本文所指,胜肽配體是指共價結合至分子支架的胜肽。通常,這樣的胜肽包括兩個或更多個能夠與支架形成共價鍵的反應性基團(即半胱胺酸殘基),以及包含在該反應性基團之間被稱為環序列的序列,因為當胜肽結合至支架上時形成環。在這樣的情況下,胜肽包括選自半胱胺酸、3-巰基丙酸(3-mercaptopropionic acid)及/或半胱胺的至少三個反應性基團,並在支架上形成至少兩個環。
藥學上可接受的鹽類
應當理解的是,鹽之形式在本發明的範圍內,且提及到胜肽配體時,包含所述配體的鹽形式。
本發明的鹽類可透過常規化學方法(諸如在《藥用鹽類:性質、選擇及用途》,P.Heinrich Stahl(編輯)、Camille G.Wermuth(編輯),ISBN:3-90639-026-8,Hardcover,388頁,2002年8月中描述的方法)由含有鹼性或酸性部分母體化合物合成。一般來說,這些鹽類可以透過使這些化合物的游離酸或鹼形式與適當的鹼或酸在水中、或在有機溶劑中或在兩者的混合物中反應以製備。
可以用多種無機及有機酸形成酸加成鹽(單鹽或雙鹽)。酸加成鹽的實例包含與選自乙酸、2,2-二氯乙酸、己二酸、藻酸、抗壞血酸(例如L-抗壞血酸)、L-天冬胺酸、苯磺酸、苯甲酸、4-乙醯胺基苯甲酸、丁酸、(+)樟腦、樟腦-磺酸、(+)-(1S)-樟腦-10-磺酸、癸酸(capric)、己酸(caproic)、辛酸、肉桂酸、檸檬酸、環己烷氨基磺酸(cyclamic)、十二烷基硫酸、乙烷-1,2-二磺酸、乙磺酸、2-羥基乙磺酸、甲酸、丁烯二酸(fumaric)、半乳糖二酸(galactaric)、2,5-二羥苯甲酸(gentisic)、葡萄糖甲酸、D-葡萄糖酸、葡萄糖醛酸(例如D-葡萄糖醛酸)、麩胺酸(例如L-麩胺酸)、α-氧代戊二酸、乙醇酸、苯甲醯胺乙酸(hippuric)、氫鹵酸(例如氫溴酸、氫氯酸、氫碘酸)、2-羥乙基磺酸、乳酸(例如(+)-L-乳酸、(±)-DL-乳酸)、乳糖酸(lactobionic)、順丁烯二酸、羥丁二酸(malic)、(-)-L-羥丁二酸、丙二酸、(±)-DL-杏仁酸、甲磺酸、萘-2-磺酸、萘-1,5-二磺酸、1-羥基-2-萘甲酸、菸鹼酸、硝酸、油酸、乳清酸(orotic)、草酸、棕櫚酸、撲酸(pamoic)、磷酸、丙酸、丙酮酸、L-焦麩胺酸、水楊酸、4-胺基水楊酸、癸二酸、硬脂酸、琥珀酸、硫酸、單寧酸、(+)-L-酒石酸、硫氰酸、對甲苯磺酸、十一碳烯酸及戊酸、以及醯化的胺基酸及陽離子交換樹脂的酸形成的單鹽或雙鹽。
一種特定的鹽由乙酸、鹽酸、氫氟酸、磷酸、硝酸、硫酸、檸檬酸、乳酸、琥珀酸(succinic)、順丁烯二酸(maleic)、羥丁二酸(malic)、羥乙基磺酸(isethionic)、丁烯二酸(fumaric)、苯磺酸、對甲苯磺酸、硫酸、甲磺酸(甲磺酸酯)(methanesulfonie(mesylate))、乙磺酸、萘磺酸、戊酸、丙酸、丁酸、丙二酸、葡萄糖醛酸及乳糖酸所形成的鹽所組成。一種特定的鹽是鹽酸鹽。另一種特定的鹽是乙酸鹽。
如果化合物是陰離子的,或具有可以是陰離子的官能團(例如,-COOH可以是-COO-),則可以與有機或無機鹼形成鹽,從而產生合適的陽離子。
合適的無機陽離子的實例包含但不限於鹼金屬離子(諸如Li+、Na+及K+)、鹼土金屬陽離子(諸如Ca2+及Mg2+)以及其他陽離子(諸如Al3+或Zn+)。合適的有機陽離子的實例包含但不限於銨離子(即,NH4 +)及被取代的銨離子(例如,NH3R+、NH2R2+、NHR3+、NR4+)。一些合適的被取代的銨離子的實例是衍生自以下的那些:甲胺、乙胺、二乙胺、丙胺、二環己胺、三乙胺、丁胺、乙二胺、乙醇胺、二乙醇胺、哌嗪、芐胺、苯基芐胺、膽鹼(choline)、葡甲胺(meglumine)及三甲胺(tromethamine)以及胺基酸(諸如離胺酸及精胺酸)。常見的季銨離子的一實例是N(CH3)4 +。
當本發明的化合物具有胺官能基時,它們可以例如根據技術人員熟知的方法與烷基化劑反應形成季銨鹽。這樣的季銨化合物在本發明的範圍內。
改質衍生物
應當理解的是,本文定義的胜肽配體的改質衍生物在本發明的範圍內。此類合適的改質衍生物的實例包含一或多種選自以下的改質:N-末端及/或C-末端改質;用一或以多個非天然胺基酸殘基取代一或多個胺基酸殘基(諸如用一或多種等位或等電子胺基酸取代一或多個極性胺基酸殘基;用其他非天然等位或等電子胺基酸取代一或多種非極性胺基酸殘基);間隔基團的添加;用一或多個抗氧化胺基酸殘基取代一或多個對氧化敏感的胺基酸殘基;用丙胺酸取代一或多個胺基酸殘基、用一或多個D-胺基酸殘基取代一或多個L-胺基酸殘基;雙環肽配體中一或多個醯胺鍵的N-烷基化;用取代鍵取代一或多個胜肽鍵;胜肽主鏈長度改質;一或多個胺基酸殘基的α-碳上的氫被另一個化學基團取代,用合適的胺、硫醇、羧酸及酚反應性試劑改質胺基酸(諸如半胱胺酸、離胺酸(lysine)、麩胺酸/天冬胺酸及酪胺酸),以使該胺基酸官能化、以及引入或
取代引入適合於官能化的正交反應性的胺基酸,例如分別允許與炔或含疊氮化物部分官能化的含疊氮化物或炔基的胺基酸。
於一實施例中,改質的衍生物包括N-末端及/或C-末端改質。於再一實施例中,其中改質的衍生物包括使用合適的胺基反應化學的N-末端改質及/或使用合適的羧基反應化學的C-末端改質。於再一實施例中,該N-末端或C-末端改質包括添加效應物基團(effector group),該效應物基團包含但不限於細胞毒性劑、放射螯合劑或發色團。
於再一實施例中,改質的衍生物包括N-末端改質。於再一實施例中,N-末端改質包括N-末端乙醯基。於該實施例中,在胜肽合成過程中,N-末端半胱胺酸基團(在本文中稱為Ci的基團)被乙酸酐或其他合適的試劑封端,從而導致分子被N-末端乙醯化。該實施例提供了去除胺基胜肽酶的潛在識別點的優點,並且避免了雙環肽降解的可能性。
於一替代實施例中,N-末端改質包括添加分子間隔基團,該分子間隔基團促進效應物基團的結合,並保持雙環肽對其標靶的效力。
於再一實施例中,改質的衍生物包括C-末端改質。於再一實施例中,C-末端改質包含醯胺基。於該實施例中,在胜肽合成過程中,將C-末端半胱胺酸基團(本文中稱為Ciii的基團)合成為醯胺,從而導致分子被C-末端醯胺化。該實施例提供了去除羧胜肽酶的潛在識別點的優點,並降低了雙環肽的蛋白水解降解的可能性。
於一實施例中,改質的衍生物包括用一或多個非天然胺基酸殘基取代一或多個胺基酸殘基。於該實施例中,可以選擇具有等位/等電子側鏈的非天然胺基酸,其既不被降解蛋白酶識別,也不對標靶效力產生任何不利影響。
或者是,可以使用具有受約束的胺基酸側鏈的非天然胺基酸,使得附近的胜肽鍵的蛋白水解在構象及空間上受到阻礙。特別是,這些涉及脯胺
酸類似物、龐大的側鏈、Cα-二取代的衍生物(例如胺基異丁酸,Aib)及環胺基酸、簡單的衍生物是胺基-環丙基羧酸。
於一實施例中,改質的衍生物包括添加間隔基團。於再一實施例中,改質的衍生物包括在N-端半胱胺酸(Ci)及/或C-端半胱胺酸(Ciii)上添加間隔基團。
於一實施例中,改質的衍生物包括用一或多個抗氧化胺基酸殘基取代一或多個對氧化敏感的胺基酸殘基。於再一實施例中,改質的衍生物包括用萘丙胺酸或丙胺酸殘基取代色胺酸殘基。該實施例提供了改善所得雙環肽配體的藥物穩定性特徵的優點。
於一實施例中,改質的衍生物包括用一或多個疏水性胺基酸殘基取代一或多個帶電荷的胺基酸殘基。於一替代實施例中,改質的衍生物包括用一或多個帶電荷的胺基酸殘基取代一或多個疏水性胺基酸殘基。帶電荷的與疏水性的胺基酸殘基的正確平衡是雙環肽配體的重要特徵。例如,疏水性胺基酸殘基會影響血漿蛋白結合的程度,並因此影響血漿中游離可用組分的濃度,而帶電荷的胺基酸殘基(特別是精氨酸)可能會影響胜肽與細胞表面磷脂膜的相互作用。兩者的組合可能會影響半衰期、胜肽藥物的分佈量及暴露量,並且可以根據臨床終點訂製。此外,帶電荷的與疏水性胺基酸殘基的正確組合及數量可以減少注射部位的刺激性(如果胜肽藥物已透過皮下給藥)。
於一實施例中,改質的衍生物包括用一或多個D-胺基酸殘基取代一或多個L-胺基酸殘基。據信該實施例透過立體阻礙(steric hindrance)來增加蛋白水解穩定性,並透過D-胺基酸的傾向來穩定β-轉構型(β-turn conformation)(Tugyi等(2005)PNAS,102(2),413-418)。
於一實施例中,改質的衍生物包括去除任何氨基酸殘基並且用丙胺酸取代。該實施例提供了去除潛在的蛋白水解攻擊位點的優點。
應當注意的是,每個上述改質都用於謹慎地改善胜肽的效力或穩定性。透過以下機制,可以基於改質進一步提高效能:
-結合利用疏水作用並導致較低的失效率的疏水部分,從而實現更高的親和力;
-結合利用遠程離子相互作用的帶電性基團,從而導致更快的速率及更高的親和力(參見例如Schreiber等人,Rapid,electrostatically assisted association of proteins(1996),Nature Struct.Biol.3,427-31);以及
-例如透過正確地約束胺基酸的側鏈以在標靶結合時熵的損失最小,藉由限制骨架的扭轉角以在標靶結合時熵的損失最小,並出於相同的原因引入另外的環化作用,從而將其他約束條件結合到胜肽中。
(綜上所述,請參見Gentilucci等人,Curr.Pharmaceutical Design,(2010),16,3185-203,和Nestor等人,Curr.Medicinal Chem(2009),16,4399-418)。
同位素變異(Isotopic variations)
本發明包含本發明的所有藥學上可接受的(放射性)同位素標記的胜肽配體,其中一或多個原子被具有相同原子序但原子量或質量數不同於通常在自然界中發現的原子量或質量數的原子取代,以及其中連接了金屬螯合基團(稱為「效應物」)能夠保持相關的(放射性)同位素之本發明的胜肽配體,以及其中某些官能基團被相關的(放射性)同位素或同位素標記的官能基團共價取代之本發明的胜肽配體。
適用於包含在本發明的胜肽配體中的同位素的實例包括氫(諸如2H(D)及3H(T))、碳(諸如11C、13C及14C)、氯(諸如36Cl)、氟(諸如18F)、碘(諸如123I、125I及131I)、氮(諸如13N及15N)、氧(諸如15O、17O及18O)、磷
(諸如32P)、硫(諸如35S)、銅(諸如64Cu)、鎵(諸如67Ga或68Ga)、釔(諸如90Y)及鎦(諸如177Lu)以及鉍(諸如213Bi)的同位素。
本發明的某些同位素標記的胜肽配體,例如摻入放射性同位素的胜肽配體,可用於藥物及/或基質組織分佈研究,並在臨床上評估疾病組織上是否存在Nectin-4標靶。本發明的胜肽配體還可具有有價值的診斷特性,因為它們可用於檢測或鑑定標記的化合物與其他分子、胜肽、蛋白質、酶或受體之間的複合物的形成。該檢測或鑑定方法可以使用用標記劑標記的化合物,諸如放射性同位素、酶、螢光物質、發光物質(例如,發光胺(luminol)、發光胺衍生物、螢光素(luciferin)、水母素(aequorin)及螢光素酶(luciferase))等。放射性同位素為氚同位素,即3H(T)及碳-14,即14C,由於它們易於摻入及現成的檢測手段,因此對於此目的特別有用。
用較重的同位素(諸如氘,即2H(D))取代,可以提供某些來自於更高的代謝穩定性的治療優點,例如增加體內半衰期或減少劑量需求,並因此在某些情況下可能是較佳的。
用正電子發射同位素(諸如11C、18F、15O及13N)取代可用於正電子發射形貌(PET)研究中,以檢查目標佔有率。
通常可以透過本領域技術人員已知的常規技術或透過所附實例中描述的類似製程,使用適當的同位素標記試劑代替先前使用的非標記試劑,來製備本發明的胜肽配體的同位素標記化合物。
合成
本發明的胜肽可以透過標準技術合成製備,然後與體外分子支架反應。當進行此操作時,可以使用標準化學法。此舉可以快速大規模地製備可
溶性材料,以用於進一步的下游實驗或驗證。可以使用諸如Timmerman等人(同上)中揭示的常規化學法來完成此種方法。
因此,本發明還涉及如本文所述選擇的多胜肽或共軛物的製備,其中製備包括任選如下所述的進一步步驟。於一實施例中,這些步驟在透過化學合成製備的最終產物多胜肽/共軛物上進行。
當製備共軛物或複合物時,目標多肽中的胺基酸殘基可任選被取代。
胜肽也可以延伸以摻入例如另一個環,並因此引入多種特異性。
為了延伸胜肽,可以使用標準固相或溶液相化學法,使用正交保護的離胺酸(及類似物)簡單地在其N-端或C-端或環內進行化學延伸。可以使用標準的(生物)共軛技術來引入活化的或可活化的N-或C-末端。或者是,可以透過片段縮合或天然化學連接,例如在(Dawson等,Synthesis of Proteins by Native Chemical Ligation.Science 266:776-779)中所描述,或透過酶,例如使用如在(Chang等,Proc Natl Acad Sci US A.1994。12月20日;91(26):12544-8或Hikari等人的Bioorganic&Medicinal Chemistry Letters第18卷,第22期,2008年11月15日,第6000-6003頁)中所描述的枯草連接酶(subtiligase)。
或者是,可以透過二硫鍵的進一步共軛來延伸或改質胜肽。這具有額外的優點,即允許第一及第二胜肽在細胞的還原環境中彼此解離一次。在這種情況下,可以在第一胜肽的化學合成過程中加入分子支架(例如TATA),以便與三個半胱胺酸基團反應;然後可以將另一個半胱胺酸或硫醇附加到第一個胜肽的N-或C-末端,這樣該半胱胺酸或硫醇僅與第二胜肽的游離半胱胺酸或硫醇反應,形成二硫鍵連接的雙環胜肽-胜肽共軛物。
類似的技術同樣適用於兩個雙環及雙特異性大環的合成/偶合,潛在地產生四特異性分子。
此外,可以使用適當的化學法,以相同的方式在N-或C-末端或經由側鏈偶合添加其他官能基團或效應物基團。於一實施例中,以不阻礙任何一個個體活動的方式進行偶合。
醫藥組合物
根據本發明的另一態樣,提供了一種醫藥組合物,其包括與一或多種藥學上可接受的賦形劑組合的本文所定義的胜肽配體。
通常,本發明的胜肽配體將以純化形式與藥理學上合適的賦形劑或載體一起使用。通常這些賦形劑或載體包含水性或醇/水溶液、乳液或懸浮液,包含鹽水及/或緩衝介質。腸胃外載體包含氯化鈉溶液、林格氏葡萄糖(Ringer's dextrose)、葡萄糖及氯化鈉以及乳酸林格氏溶液(lactated Ringer's)。如果需要使多胜肽複合物保持懸浮狀態,則合適的生理學可接受的佐劑可以選自增稠劑,諸如羧甲基纖維素、聚乙烯吡咯烷酮、明膠及藻酸鹽。
靜脈內載體包含液體及營養補充劑以及電解質補充劑,諸如基於林格氏葡萄糖的那些。也可能存在防腐劑和其他添加劑,諸如抗微生物劑、抗氧化劑、螯合劑及惰性氣體(Mack(1982)Remington's Pharmaceutical Sciences,第16版)。
本發明的胜肽配體可以用作單獨施用的組合物或與其他試劑聯用。這些可以包含抗體、抗體片段及各種免疫治療藥物(諸如環孢黴素、甲胺蝶呤、阿黴素或順鉑(cisplatinum))以及免疫毒素。醫藥組合物可以包含各種細胞毒性或其他試劑的「雞尾酒」與本發明的蛋白質配體結合,或甚至根據本發明所選擇的具有不同特異性的多胜肽的組合,諸如使用不同標靶配體選擇的多胜肽,無論是否在給藥之前合併。
根據本發明的醫藥組合物的給藥途徑可以是本領域普通技術人員通常已知的任何途徑。為了治療可以根據標準技術將本發明的胜肽配體施用於任何患者。給藥可以透過任何合適的方式進行,包含腸胃外、靜脈內、肌肉內、腹膜內、經皮、或者透過肺部途徑,或者也適當地透過導管直接輸注。較佳地,根據本發明的醫藥組合物將透過吸入給藥。給藥的劑量及頻率將取決於患者的年齡、性別及狀況、同時給藥的其他藥物、禁忌症及臨床醫生要考慮的其他參數。
可以凍乾本發明的胜肽配體用於儲存,並在使用前在合適的載體中重組。已經表明該技術是有效的,並且可以採用本領域已知的凍乾及重組技術。本領域技術人員應當理解的是,凍乾及重組會導致不同程度的活性損失,並且可能必須向上調整量以進行補償。
可以施用含有本發明的胜肽配體或其混合物的組合物以進行預防及/或治療。於某些治療應用中,將足以完成所選細胞群的至少部分抑制、壓制、調節、殺傷或某些其他可測量參數的量定義為「治療有效劑量」。達到此劑量所需的量將取決於疾病的嚴重程度及患者自體免疫系統的一般狀態,但通常為每千克體重0.005至5.0mg所選胜肽配體,劑量為0.05至2.0mg/kg/劑更常用。對於預防性應用,也可以相似或稍低的劑量施用含有本發明的胜肽配體或其混合物的組合物。
可以將根據本發明的含有胜肽配體的組合物用於預防及治療環境,以幫助哺乳動物中所選標靶細胞群的改變、失活、殺死或去除。此外,本文所述的胜肽配體可在體外或體外選擇性地用於殺死、消耗或以其他方式有效地從異質細胞集合中去除標靶細胞群。可以將來自哺乳動物的血液與所選的胜
肽配體體外結合,從而根據標準技術將不需要的細胞殺死或以其他方式從血液中去除以返回哺乳動物。
治療用途
根據本發明的再一態樣,提供了如本文所定義的用於預防、抑制或治療癌症的異質雙環肽複合物。
可以治療(或抑制)的癌症(及其良性對應物)的實例包含但不限於上皮源性腫瘤(腺瘤及各種類型的癌,包含腺癌、鱗狀癌、移行細胞癌及其他癌),諸如膀胱癌及泌尿道癌、乳癌、胃腸道癌(包含食道、胃(stomach)(胃(gastric))、小腸、結腸、直腸及肛門)、肝癌(肝細胞癌)、膽囊癌及膽道系統癌、外分泌胰腺癌、腎臟癌、肺癌(例如腺癌、小細胞肺癌、非小細胞肺癌、支氣管肺泡癌及間皮瘤)、頭頸癌(例如舌癌、頰腔癌、喉癌、咽癌、鼻咽癌、扁桃腺癌、唾腺癌、鼻腔癌及鼻旁竇癌)、卵巢癌、輸卵管癌、腹膜癌、陰道癌、外陰癌、陰莖癌、子宮頸癌、子宮肌層癌、子宮內膜癌、甲狀腺癌(例如甲狀腺濾泡癌)、腎上腺癌、攝護腺癌、皮膚癌及附件癌(例如黑色素瘤、基底細胞癌、鱗狀細胞癌、角質棘皮瘤、增生性痣);血液系統惡性腫瘤(即白血病、淋巴瘤)及惡性血液病以及邊緣惡性腫瘤疾病(包含血液系統惡性腫瘤及淋巴譜系的相關疾病(例如急性淋巴球性白血病[ALL]、慢性淋巴球性白血病[CLL]、B-細胞淋巴瘤(諸如瀰漫性大B-細胞淋巴瘤[DLBCL])、濾泡性淋巴瘤、伯基特氏淋巴瘤(Burkitt’s lymphoma)、被套細胞淋巴瘤、T-細胞淋巴瘤及白血病、自然殺手[NK]細胞淋巴瘤、霍奇金淋巴瘤(Hodgkin’s lymphomas)、毛細胞白血病、意義不明的單株免疫球蛋白增高症、漿細胞瘤、多發性骨髓瘤、移植後淋巴增生性疾病)、以及血液系統惡性腫瘤及骨髓譜系相關疾病(例如急性骨髓性白血病[AML]、慢性骨隨性白血病[CML]、慢性骨髓
單核細胞白血病(chronic myelomonocytic leukemia)[CMML]、嗜酸性白血球增多症、骨髓增生疾病(諸如多發性紅細胞增多症、原發性血小板增多症及原發性骨髓纖維化、骨髓增生性症候群、骨髓發育不良症候群及早幼粒細胞白血病))、間質起源的腫瘤(tumors of mesenchymal origin)(例如軟組織、骨或軟骨肉瘤(諸如骨肉瘤、纖維肉瘤、軟骨肉瘤、橫紋肌肉瘤、平滑肌肉瘤、脂肉瘤、血管肉瘤、卡波西氏肉瘤(Kaposi’s sarcoma)、尤因氏肉瘤(Ewing’s sarcoma)、滑膜肉瘤(synovial sarcoma)、上皮樣肉瘤、胃腸道間質瘤、良性及惡性組織細胞瘤及隆突性皮膚纖維肉瘤(dermatofibrosarcoma protuberan)))、中樞或周圍神經系統腫瘤(例如星形細胞瘤、神經膠質瘤及神經膠質母細胞瘤、腦膜瘤、室管膜瘤、松果體瘤及神經鞘瘤);內分泌腫瘤(例如腦下垂體瘤、腎上腺腫瘤、胰島細胞瘤、副甲狀腺腫瘤(parathyroid tumor),癌樣瘤及甲狀腺髓質癌);眼及附件腫瘤(例如網膜芽細胞瘤);生殖細胞及滋養細胞腫瘤(例如畸胎瘤、精原細胞瘤、惡性胚胎瘤、水囊狀胎塊(hydatidiform moles)及絨毛膜癌);以及小兒及胚胎腫瘤(例如髓母細胞瘤、神經母細胞瘤,威爾姆斯瘤(Wilms tumor)及原始神經外胚層腫瘤);或先天性或其他形式的綜合症,使患者容易患惡性腫瘤(例如著色性乾皮病(Xeroderma Pigmentosum))。
於再一實施例中,癌症是選自造血系統惡性腫瘤,諸如選自:非霍奇金淋巴瘤(NHL)、伯基特淋巴瘤(BL)、多發性骨髓瘤(MM)、B慢性淋巴細胞性白血病(B-CLL)、B及T急性淋巴細胞白血病(ALL)、T細胞淋巴瘤(TCL)、急性骨髓性細胞白血病(AML)、毛細胞白血病(HCL)、霍奇金淋巴瘤(HL)及慢性骨髓性細胞白血病(CML)。
本文提到的術語「預防」涉及在誘導疾病之前給予保護性組合物。「抑制」是指在誘導事件之後,但在疾病的臨床表現之前給予組合物。「治療」涉及在疾病症狀變得明顯之後給予保護性組合物。
有可用於篩選胜肽配體在預防或治療疾病中的有效性的動物模型系統。本發明促進了動物模型系統的使用,這允許開發可以與人及動物標靶交叉反應的多肽配體,從而允許使用動物模型。
本發明將如下參考下列實施例進一步描述。
實施例
通常,本發明的異質雙環肽複合物可以根據以下常規方法製備:
將所有溶劑脫氣,並用N2吹掃3次。將BP-23825(1.0eq)、HATU(1.2eq)及DIEA(2.0eq)的DMF溶液混合5分鐘,然後加入Bicycle1(1.2eq。)。將反應混合物在40℃下攪拌16小時。然後將反應混合物減壓濃縮以除去溶劑,並透過製備級HPLC純化,得到中間體2。
將中間體2(1.0eq)及Bicycle2(2.0eq)的混合物溶解於t-BuOH/H2O(1:1),然後加入CuSO4(1.0eq)、VcNa(4.0eq)及THPTA(2.0eq)。最後,加入0.2M NH4HCO3以將pH調整至8。將反應混合物在N2氣氛下於40℃攪拌16小時。透過製備級HPLC直接純化反應混合物。
下文將提供本發明的異質雙環肽複合物的更詳細的實驗:
實施例1:合成BCY11863
BCY12476的製備步驟
將N-(酸-PEG3)-N-雙(PEG3-疊氮化物)(70.0mg,112.2μmol,1.0eq)、HATU(51.2mg,134.7μmol,1.2eq)及DIEA(29.0mg,224.4μmol,40μL,2.0eq)的混合物溶解在DMF(2mL)中,混合5分鐘。然後加入BCY8116
(294.0mg,135.3μmol,1.2eq)。將反應混合物在40℃下攪拌16小時。LC-MS顯示一個具有所需的m/z主峰。減壓濃縮反應混合物以除去溶劑並產生殘餘物。然後將殘餘物通過製備級HPLC純化。獲得為白色固體的BCY12476(194.5mg,66.02μmol,產率29%,純度94%)。計算的MW:2778.17,觀察到的m/z:1389.3([M+2H]2+),926.7([M+3H]3+)。
BCY11863的製備步驟
首先將BCY12476(100.0mg,36.0μmol,1.0eq)、BCY8928(160.0mg,72.0μmol,2.0eq)的混合物溶於2mL的t-BuOH/H2O(1:1),然後加入CuSO4(0.4M,180μL,1.0eq)、VcNa(28.5mg,143.8μmol,4.0eq)、THPTA(31.2mg,71.8μmol,2.0eq)。最後,加入0.2M NH4HCO3將pH調整至8。將此處的所有溶劑脫氣並用N2吹掃。將反應混合物在N2氣氛下在40℃攪拌16小時。LC-MS顯示剩餘BCY8928,並且還檢測到所需的m/z。反應混合物透過製備級HPLC直接純化。第一次純化得到TFA鹽形式的BCY11863(117.7mg,15.22μmol,產率42.29%,純度93.29%),而純度較低的級分再次透過製備級HPLC純化,得到BCY11863(33.2mg,4.3μmol,產率12%,95%純度)為TFA鹽。計算的MW:7213.32,觀察到的m/z:1444.0([M+5H]5+)。
實施例2:合成BCY13390
BCY13689的合成步驟
將BCY12476(47.0mg,16.91μmol,1.0eq)、BCY8928(30.0mg,13.53μmol,0.8eq)及THPTA(36.7mg,84.55μmol,5.0eq)的混合物溶於t-BuOH/H2O(1:1,8mL,預脫氣並用N2吹掃),然後在N2下添加CuSO4(0.4M,21.0μL,0.5eq)及VcNa(67.0mg,338.21μmol,20.0eq)。透過滴加0.2M NH4HCO3(在1:1 t-BuOH/H2O中)將該溶液的pH調整至8,溶液變為淺
黃色。將反應混合物在N2氣氛下在25℃攪拌1.5小時。LC-MS顯示剩餘一些BCY12476,BCY8928被完全消耗,並且檢測到具有所需m/z的峰。過濾反應混合物並減壓濃縮,得到殘餘物。透過製備級HPLC純化粗產物,得到為白色固體的BCY13689(25.3mg,4.56μmol,產率27%,純度90%)。計算的MW:4995.74,觀察到的m/z:1249.4([M+4H]4+),999.9([M+5H]5+)。
BCY13390的製備步驟
將BCY13689(43.6mg,8.73μmol,1.0eq)、BCY13389(20.8mg,9.16μmol,1.05eq)及THPTA(3.8mg,8.73μmol,1.0eq)的混合物溶於t-BuOH/H2O(1:1,1mL,預脫氣並用N2吹掃),然後在N2下加入CuSO4(0.4M,22.0μL,1.0eq)及VcNa(3.5mg,17.45μmol,2.0eq)。透過滴加0.2M NH4HCO3(在1:1 t-BuOH/H2O中)將該溶液的pH調整至8,溶液變為淺黃色。將反應混合物在N2氣氛下在25℃攪拌2小時。LC-MS顯示一個與所需的m/z相對應明顯的峰。過濾反應混合物並減壓濃縮,得到殘餘物。透過製備型HPLC純化粗產物,得到為白色固體的BCY13390(33.8mg,4.21μmol,產率48%,純度90%)。計算分子量:7270.41,觀察到的m/z:1454.9([M+5H]5+),1213.2([M+6H]6+)。
實施例3:合成BCY13582
BCY13582的製造步驟
將BCY13390(5.0mg,0.6μmol,1.0eq)、生物素-PEG12-NHS酯(CAS 365441-71-0,0.7mg,0.72μmol,1.1eq)的混合物溶於MeCN/H2O(1:1,2mL)。透過滴加1.0M NaHCO3將該溶液的pH調整至8。將反應混合物在25℃下攪拌0.5小時。LC-MS顯示BCY13390已完全耗盡,並檢測到一個具有所需m/z的主峰。過濾反應混合物並減壓濃縮,得到殘餘物。透過製備級HPLC純化粗產物,得到為白色固體的BCY13582(2.5mg,0.30μmol,產率43%,純度96%)。計算的MW:8096.43,觀察到的m/z:1351.1([M+6H]6+),1158.5([M+7H]7+)。
實施例4:合成BCY13583
BCY13583的製備步驟
將BCY13390(15.0mg,2.06μmol,1.0eq)及Alexa fluor® 488 NHS酯(2.5mg,4.12μmol,2.0eq)的混合物溶於DMF(0.5mL)。然後滴加DIEA(2.6mg,20.63μmol,3.6μL,10eq)。將反應混合物在25℃下攪拌1小時。LC-MS顯示剩餘BCY13390,並且檢測到一個具有所需m/z的主峰。將另外的
Alexa fluor® 488 NHS酯(2.0mg,3.09μmol,1.5eq)添加到反應混合物中,並將該反應混合物在25℃下再攪拌一小時。HPLC顯示BCY13390被完全消耗。過濾反應混合物並減壓濃縮,得到殘餘物。透過製備級HPLC純化粗產物,得到為紅色固體的BCY13583(5mg,0.61μmol,產率29%,純度95%)。計算的MW:7787.9,觀察到的m/z:1948.8([M+4H+H2O]4+),1558.6([M+5H+H2O]5+),1299.1([M+7H+H2O]7+)。
實施例5:合成BCY13628
BCY13628的製備步驟
將BCY13390(5.6mg,0.77μmol,1.0eq)及花青5 NHS酯(0.5mg,0.85μmol,1.1eq)的混合物溶於MeCN/H2O(1:1,2mL)。透過滴加1.0M NaHCO3將該溶液的pH調整至8。將反應混合物在25℃下攪拌0.5小時。LC-MS顯示BCY13390已完全耗盡,並檢測到一個具有所需m/z的主峰。過濾反應混合物並減壓濃縮,得到殘餘物。透過製備級HPLC純化粗產物,得到為藍色固體的BCY13628(2.9mg,0.36μmol,產率46%,純度95%)。計算的MW:7736.06,觀察到的m/z:1289.9([M+6H]6+),1105.5([M+7H]7+)。
實施例6:合成BCY15155
BCY15155的製備步驟
將BCY13689(25.0mg,5.00μmol,1.0eq)、BCY14601(13.0mg,6.01μmol,1.2eq)及THPTA(2.0mg,5.00μmol,1.0eq)的混合物溶於t-BuOH/0.2M NH4HCO3(1:1、0.5mL,預脫氣並用N2吹掃),然後在N2下加入CuSO4(0.4M,12.5μL,1.0eq)及Vc(3.5mg,20.02μmol,4.0eq)。將該溶液的pH調整至8,溶液變為淺黃色。將反應混合物在N2氣氛下在25℃攪拌2小
時。LC-MS顯示BCY13689已完全耗盡,剩餘了一些BCY14601,並檢測到一個具有所需m/z的主峰。過濾反應混合物並減壓濃縮,得到殘餘物。粗產物透過製備級HPLC純化,得到為白色故體的BCY15155(19.7mg,2.41μmol,收率36%,純度97%)。計算的MW:7171.3,觀察到的m/z:1434.7([M+5H]5+),1196.2([M+6H]6+)。
實施例7:合成BCY14602
BCY14602的製備步驟
將BCY12476(100.0mg,36.00μmol,1.0eq)、BCY14601(158.0mg,72.63μmol,2.04eq)及THPTA(15.6mg,36.00μmol,1.0eq)的混合物溶於t-BuOH/0.2M NH4HCO3(1:1,2mL,預脫氣並用N2吹掃),然後在N2下加入CuSO4(0.4M,89.0μL,1.0eq)及VcNa(28.5mg,143.98μmol,4.0eq)。將該溶液的pH調整至8,溶液變為淺黃色。將THPTA及VcNa補充兩次,然後將整體溶液在N2氣氛下於25℃攪拌48小時。LC-MS顯示BCY12476已完全耗盡,剩餘BCY14601並檢測到一個具有所需m/z的主峰。還檢測到一些副產物。過濾反應混合物並減壓濃縮,得到殘餘物。粗產物透過製備級HPLC純化,得到為白色固體的BCY14602(45.2mg,5.51μmol,產率15%,純度86%)。計算的MW:7129.2,觀察到的m/z:1426.6([M+5H]5+),1189.1([M+6H]6+)。
分析數據
使用質譜及HPLC分析以下本發明的異質雙環肽複合物。HPLC設置如下:
移動相:A:0.1%TFA於H2O中B:0.1%TFA於ACN中
流量:1.0ml/min
管柱:Gemini-NX C18 5um 110A 150*4.6mm
儀器:Agilent 1200 HPLC-BE(1-614)
所用梯度在20分鐘內為30-60%B,數據生成如下:
生物數據
1. CD137報導基因分析(Reporter Assay)與腫瘤細胞的共培養
透過向RPMI-1640(Promega試劑盒CS196005的成分)中添加1%FBS來製備稱為R1培養基的培養基。在無菌的96孔盤上製備R1中測試物品的系列稀釋液。將每孔25μL的測試物品或R1(作為背景控制組)添加到白細胞培養盤中的指定孔中。收集腫瘤細胞*,並以400,000細胞/mL的濃度重新懸浮在R1培養基中。將二十五(25)μL/孔的腫瘤細胞添加至白細胞培養盤。將Jurkat細胞(Promega試劑盒CS196005,0.5mL)在水浴中解凍,然後添加到5ml回溫的R1培養基中。然後將二十五(25)μL/孔的Jurkat細胞添加到白細胞培養板中。將細胞及測試物品在37℃,5%CO2下培養6小時。在6小時結束時,加入75μL/孔的Bio-GloTM試劑(Promega),培養10分鐘,然後在盤式分析儀(Clariostar,BMG)中讀取螢光。計算相對於單獨細胞的倍數變化(Jurkat細胞+共培養中使用的細胞株),並在GraphPad Prism中繪製為log(促效劑)對上響應,以確定EC50(nM)及背景誘導倍數(Max)。
共培養中使用的腫瘤細胞類型為NCI-H292、CT26#7、MC38#13、HT1376、NCI-H322及T47D,已顯示可表達Nectin-4。
圖1A中顯示的數據表明,Nectin-4/CD137異質(BCY11863)在CD137報導基因分析中誘導了強烈的CD137活性,並且該活性取決於異質與CD137的結合。BCY11617是一種分子,其中CD137雙環肽由所有消除結合而不誘導CD137促效作用的D-胺基酸組成。
下表1報導了由異質雙環肽複合物BCY11863及緊密類似物在與Nectin-4表達的腫瘤細胞株共培養的CD137報導基因分析中誘導的總EC50(nM)。該數據證明了BCY11863在與具有一定範圍Nectin-4表達的細胞株共培養中誘導CD137促效作用的潛力。
2.人類PBMC共培養(細胞激素釋放)測定
根據供應商的建議培養人類及小鼠腫瘤細胞株。將來自健康人類供體的冷凍PBMC解凍,並在室溫PBS中洗滌一次,然後重新懸浮於R10培養基中。將100μl PBMC(1,000,000 PBMCs/ml)及100μl腫瘤細胞(100,000腫瘤細
胞/ml)(效應子:標靶細胞比(E:T)10:1)鋪在96孔盤的每個孔中用於共培養測定。在第0天將100ng/ml的可溶性抗CD3mAb(殖株OKT3)加入培養物中以刺激人類PBMC。將測試化合物、控制組化合物或媒介物控制組在R10培養基中稀釋,並向各孔中加入50μL,使每孔的最終體積達到250μL。盤上覆蓋有透氣膜,並在37℃、5%CO2的加濕室中培養三天。刺激後48小時收集上清液,由Luminex檢測到人類IL-2和IFNγ。簡而言之,將標準品及樣品添加到黑色96孔盤中。加入微粒混合物(由Luminex試劑盒,R&D Systems提供),在室溫下搖動2小時。使用磁性保持器將盤洗滌3次。然後將生物素混合物加到盤中,並在室溫下搖動1小時。使用磁性保持器將盤洗滌3次。將鏈黴親和素混合物加到盤中,並在室溫下搖動30分鐘。使用磁力架將盤洗滌3次,重新懸浮於100μL洗滌緩衝液中,在室溫下搖動2分鐘,然後使用Luminex 2000讀取。使用內置的Luminex軟體分析原始數據,以生成標準曲線並內插蛋白質濃度,所有其他數據分析和繪圖均使用Excel和Prism軟體進行。數據代表使用三個技術性相似物進行測試的3-5個獨立供體PBMC的研究。
圖2A及圖2B中顯示的數據表明,在PBMC-4T1共培養測定中,Nectin-4/CD137異質(BCY11863)誘導了穩健的IL-2及IFN-γ細胞激素分泌。BCY11617是結合Nectin-4但不結合CD137的陰性對照。
下表2及圖2報導了在人類PBMC共培養(細胞激素釋放)測定中由選定的Nectin-4/CD137異質雙環肽複合物誘導的EC50(nM)及最大IFN-γ細胞激素分泌(pg/ml)的總結。這證明了BCY11863在表達Nectin-4的許多不同腫瘤細胞株存在下誘導細胞激素分泌的潛力。
3. Nectin-4/CD137異質BCY11863在SD大鼠中的藥物動力學
雄性SD大鼠透過靜脈推注(IV bolus)、靜脈輸注(IV infusion)(15分鐘)或皮下,以在25mM組胺酸HCl、10%蔗糖pH 7中配製的Nectin-4/CD137異質BCY11863給藥。在每個時間點透過下頜下靜脈或大隱靜脈進行連續性放血(約80μL血液/時間點)。立即將所有血液樣品轉移到含有2μL K2-EDTA(0.5M)作為抗凝劑的預冷微量離心管中,並置於濕冰上。透過在約4℃、3000g下離心立即將血液樣品處理為血漿。立即將包含內標物在內的沉澱物添加到血漿中,充分混合,並在4℃下以12,000rpm離心10分鐘。將上清液轉移到預先標記的聚丙烯微量離心管中,然後在乾冰上快速冷凍。根據需要將樣品儲存在70℃或更低的溫度下直至分析。使用Orbitrap Q Exactive以陽離子模式直接注入7.5μL上清液樣品進行LC-MS/MS分析,以確定分析物的濃度。使用Phoenix WinNonlin 6.3軟體程序透過非隔室方法分析血漿濃度與時間的數據。報導了C0、Cl、Vdss、
T1/2、AUC(0-last)、AUC(0-inf)、MRT(0-last)、MRT(0-inf)以及血漿濃度與時間曲線圖。實驗中的藥物動力學參數如表3所示:
上表3及圖5中的數據表明BCY11863是一種低清除率分子,其分佈體積大於血漿體積。此外,BCY11863的SC給藥在大鼠中的生物利用度很高。
表4及圖14中的數據顯示,當對SD大鼠靜脈給藥BCY11863時,<1%的BCY11863被代謝為BCY15155。在研究的前24小時內,未發現向BCY14602的顯著轉化。
4. Nectin-4/CD137異質BCY11863在馬來猴中的藥物動力學
非幼年馬來猴透過靜脈輸注(15或30分鐘)到頭的靜脈中,配入1mg/kg Nectin-4/CD137異質BCY11863,其由25mM組胺酸HCl、10%蔗糖pH 7配製。在每個時間點從受約束的非鎮靜動物的周圍血管中進行連續放血(約1.2ml血液/時間點),將其注入市售的在濕冰上含有鉀(K2)EDTA * 2H2O(0.85-1.15mg)的試管,並處理為血漿。收集後立即將樣品離心(在2至8℃下3,000 x g 10分鐘)。將0.1mL血漿轉移到標記的聚丙烯微量離心管中。立即將在MeOH中包含內標100ng/mL拉貝洛爾(Labetalol)& 100ng/mL地塞米松(dexamethasone)& 100ng/mL甲苯磺丁尿素(tolbutamide)& 100ng/mL維拉帕米(Verapamil)& 100ng/mL格列本脲(Glyburide)& 100ng/mL塞來昔布(Celecoxib)的5倍沉澱劑添加到血漿,充分混合,並在2至8℃下以12,000rpm離心10分鐘。將上清液樣品轉移到預先標記的聚丙烯微量離心管中,並在乾冰上冷凍。將樣品保存在-60℃或更低的溫度下,直到LC-MS/MS分析為止。將等份的40μL校準標準品、品質控制樣品、單空白樣品及雙空白樣品加到1.5mL試管中。每個樣品(雙空白樣品除外)分別用200μL IS1淬滅(雙空白樣品用200μL MeOH及0.5%tritonX-100淬滅),然後將混合物用渦旋儀充分渦旋混合(至少15s),並在4℃下於12000g離心15分鐘。使用Orbitrap Q Exactive以陽離子模式注入10μL上清液進行LC-MS/MS分析,以確定分析物的濃度。使用Phoenix WinNonlin 6.3軟體程序透過非隔室方法分析血漿濃度與時間的數據。報導了C0、Cl、Vdss、T1/2、AUC(0-last)、AUC(0-inf)、MRT(0-last)、MRT(0-inf)以及血漿濃度與時間曲線圖。兩種特異性化合物的藥物動力學參數如表5所示。
圖3顯示了SD大鼠(n=3)靜脈注射2mg/kg及馬來猴(n=2)靜脈注射1mg/kg時BCY11863的血漿濃度對上時間曲線。BCY11863在穩態(steady state)下的分佈體積(Vdss)為1.6L/kg,在大鼠中的清除率為7.7mL/min/kg,導致終末半衰期為4.1小時。BCY11863在穩態下的分佈體積(Vdss)為0.62L/kg,在馬來猴中的清除率為3.3mL/min/kg,導致終末半衰期為5.3小時。隨後的研究與這些結果一致。馬來猴IV研究中的PK參數表明,這是一種血漿清除率低的分子,其分佈體積與全身水相似。
5. Nectin-4/CD137異質BCY11863在CD1小鼠中的藥物動力學
透過腹膜內或靜脈內給藥,給予6隻雄性CD-1小鼠15mg/kg的Nectin-4/CD137異質BCY11863,其在25mM組胺酸HCl、10%蔗糖pH 7中配製。在每個時間點透過下頜下靜脈或大隱靜脈進行連續放血(約80μL血液/時間點)。立即將所有血液樣品轉移到含有2μL K2-EDTA(0.5M)作為抗凝劑的預冷微量離心管中,並置於濕冰上。立即透過在約4℃、3000g下離心處理血液樣品以進行血漿處理。立即將包含內標物在內的沉澱物加入血漿中,充分混合,然後在12,000rpm、4℃下離心10分鐘。將上清液轉移到預先標記的聚丙烯微量
離心管中,然後在乾冰上快速冷凍。根據需要將樣品儲存在70℃或更低的溫度下直至分析。使用Orbitrap Q Exactive以陽離子模式直接注入7.5μL上清液樣品進行LC-MS/MS分析,以確定分析物的濃度。使用Phoenix WinNonlin 6.3軟體程序透過非隔室方法分析血漿濃度與時間的數據。報導了C0、Cl、Vdss、T1/2、AUC(0-last)、AUC(0-inf)、MRT(0-last)、MRT(0-inf)以及血漿濃度與時間曲線圖。
圖9顯示了CD1小鼠(n=3)中IP劑量為15mg/kg時BCY11863的血漿濃度與時間的關係曲線以及BCY11863的終末血漿半衰期。
上圖9及表6中的數據顯示BCY11863可以在小鼠中以靜脈推注(IV bolus)及腹膜內(IP)給藥。BCY11863的IP給藥在小鼠中的生物利用度很高。IV研究的PK參數表明這是一種低清除率的分子,其分佈體積大於血漿體積。
6. BCY11863在同系Nectin-4過表達的MC38腫瘤模型中的抗腫瘤活性(MC38#13)
將6-8周大的C57BL/6J-hCD137雌性小鼠的腹側接種1x106個同系Nectin-4過表達的MC38細胞(MC38#13)。當腫瘤平均大小達到72mm3時,將小鼠隨機接受媒介物或BCY11863(腹膜內給藥)。每天(QD)或每三天(Q3D)以1mg/kg或10mg/kg的劑量(n=6小鼠/治療組(cohort))給予BCY11863。QD劑量的小鼠接受16劑BCY11863,Q3D劑量的小鼠接受10劑BCY11863。透過卡尺測量監測腫瘤的生長直至治療開始後第69天。該實驗的結果可見於圖4,其中在第7天及第14天時的2個治療組中觀察到腫瘤生長顯著減少(p<0.05,採用Dunnett檢驗進行2次方差分析,進行多次比較)。所有治療組與媒介物組明顯不同,到第48天,BCY11863治療的24隻動物中有22隻對治療完全緩解,並且沒有明顯的腫瘤殘留。
根據IP注射後(2.5小時)BCY11863在小鼠中的循環血漿半衰期,在BCY11863劑量(1及10mg/kg)及給藥間隔(QD及Q3D)之後,血漿波谷量將接近0,因此證明了間歇給藥方式使BCY11863的血漿暴露量少於連續暴露量,足以導致顯著的抗腫瘤活性,從而導致持久的完全緩解。
7. BCY11863治療導致對Nectin-4過表達的MC38腫瘤模型的免疫記憶
在第69天,用1x106 MC38#13-細胞再次接種對BCY11863治療完全緩解的5隻動物。用1x106 MC38#13-細胞接種一組5隻幼年C57BL/6J-hCD137雌性小鼠作為控制組。在圖5中可以看到該實驗的結果,其中所有5隻未接種的C57BL/6J-hCD137雌性小鼠在接種後第13天都生長出了腫瘤,而所有已接種的完全緩解小鼠均未出現腫瘤。這證明透過BCY11863處理獲得完全抗腫瘤反應的動物已形成免疫記憶。
8. BCY11863在同系Nectin-4過表達的CT26腫瘤模型中顯示抗腫瘤活性(CT26#7)
將6-8週齡的BALB/c-hCD137雌性小鼠的腹側接種3x105同系Nectin-4過表達的CT26細胞(CT26#7)。當腫瘤平均大小達到70mm3左右時,每三天隨機將小鼠腹膜內接受媒介物或5mg/kg BCY11863(共6劑)。透過卡尺測量監測腫瘤生長直至治療開始後第14天。從圖6中可以看到該實驗的結果,其中BCY11863治療顯著(p<0.0001,Student's檢驗)從第7天開始降低了腫瘤的生長。
根據IP注射後(2.5小時)BCY11863在小鼠中的循環血漿半衰期,在整個給藥期間,血漿暴露將不會連續進行,這表明少於連續BCY11863的血漿暴露足以導致顯著的抗腫瘤活性。
9.在最後一次(第6次)BCY11863的Q3D劑量之後1小時,CT26#7腫瘤組織中的總T細胞及CD8+T細胞增加
在最後一次媒介物或BCY11863劑量後1小時,處死帶有CD26#7的小鼠,收集腫瘤,進行單細胞懸浮液處理,並染色以進行流式細胞儀分析,用於分析總T細胞(CD45+CD3+)、CD8+T細胞(CD45+CD3+CD8+)、CD4+T細胞(CD45+CD3+CD4+)及調節性T細胞(Tregs;CD45+CD3+CD4+Foxp3+)。該實驗的結果可以在圖7中看到,可以看出BCY11863處理導致總T細胞(p<0.0001,Student's t檢驗)及CD8+T細胞(p<0.0001,Student's t檢驗)顯著增加以及CD8+T細胞/Treg比值的顯著增加(p<0.05,Student's t檢驗)。
這表明在間歇給藥後,用BCY11863進行治療可導致腫瘤組織中局部T細胞量升高。
10.在單次靜脈內(iv)施用5mg/kg BCY11863後,BCY11863在CT26#7同系腫瘤動物的血漿及腫瘤組織中的藥物動力學分佈
將6-8週齡的BALB/c雌性小鼠的腹側接種3x105同系Nectin-4過表達的CT26細胞(CT26#7)。當腫瘤平均大小達到400mm3左右時,將小鼠隨機接受單次靜脈注射的媒介物或5mg/kg BCY11863。在0.25、0.5、1、2、4、8及24小時的時間點處死一組小鼠(n=3/時間點),並分析收集的血漿及腫瘤組織中的BCY11863。對於腫瘤BCY11863含量分析,透過用10體積(w:v)均質溶液(MeOH/15mM PBS(1:2,v:v))均質腫瘤組織來製備腫瘤均質。40μL樣品用200μL IS1淬滅,將混合物以800rpm渦旋混合10分鐘,然後在4℃以3220g離心15分鐘。將上清液轉移至另一個乾淨的96孔盤並在4℃下以3220g離心5分鐘,然後注入10.0μL上清液,使用Orbitrap Q Exactive以陽離子模式下進行LC-MS/MS分析,以確定分析物的濃度。對於血漿BCY11863含量分析,將血液樣品收集在K2-EDTA管中,並透過在約4℃、3000g離心下立即處理為血漿。40μL血漿樣品用200μL IS1淬滅,將混合物以800rpm渦旋混合10分鐘,然後在4℃以3220g離心15分鐘。將上清液轉移至另一個乾淨的96孔盤中並在4℃下以3220g離心5分鐘,然後注入10.0μL上清液,使用Orbitrap Q Exactive以陽離子模式進行LC-MS/MS分析,以確定分析物的濃度。
該實驗的結果顯示在圖8中,從中可以看出,血漿BCY11863從循環中消除後,BCY11863被保留在腫瘤組織中,如BCY11863血漿T1/2(1.65小時)及腫瘤T1/2(13.4小時)的差異所示。
11. BCY11863與四種臨床前物種之間Nectin-4及CD137的結合
使用表面電漿共振(SPR)表徵BCY11863與其主要靶標Nectin-4和CD137的結合。
(a)Nectin-4
BCY11863透過5-27nM之間的KD與馬來猴、大鼠、小鼠及人Nectin-4結合,透過直接結合已被生物素化並捕獲在鏈黴親和素感測器晶片表面的細胞外結構域來測量。
為了理解在三元復合物的情況下,即當也與CD137結合時,BCY11863與Nectin-4的結合是否改變,開發了多組分SPR結合測定法。首先將BCY11863捕獲到固定在SPR晶片表面的人類CD137中,然後將來自不同物種的Nectin-4傳遞到晶片上,以確定它們與捕獲的BCY11863的親和力(參見圖10C)。Nectin-4的親和力通常在CD137結合存在下保持,如下所示:
(b)CD137
BCY11863與表面結合的CD137的直接結合無法透過SPR準確測量,因為BCY11863中的兩個CD137結合雙環產生的親合力導致非常緩慢koff(參見圖10B)。此外,馬來猴CD137的生物素化消除了BCY11863的結合,這可能是由於馬來猴蛋白上賴胺酸的改質對BCY11863的結合很重要。因此,在SPR中測試了含有C端生物素化賴胺酸(BCY13582)的BCY11863類似物,以確定BCY11863的物種間特異性。使用可逆生物素捕獲試劑盒將BCY13582捕獲到感測器晶片上,並確定了不同物種對Nectin-4的親和力。兩種策略均顯示,這些BCY11863類似物以KD<10nM與人類及馬來猴CD137結合,並且與小鼠及大鼠CD137的結合都可忽略不計。
為了了解在三元複合物的情況下BCY11863與CD137的結合是否被改變了,即當還與Nectin-4結合時,開發了雙重結合SPR結合測定法。首先將
BCY11861捕獲到固定在SPR晶片表面上的人類Nectin-4,然後將來自不同物種的可溶性CD137通過晶片,以確定它們與捕獲的BCY11863的親和力(參見圖10D)。通常在Nectin-4結合的情況下保持對CD137的親和力,如下所示:
圖10A顯示出了一個實例感測圖,其證明BCY11863以4.1nM的親和力與Nectin-4(人類)結合。圖10B顯示了BCY11863以高親和力與CD137(人類)結合的感測圖。由於BCY11863中存在2個CD137結合雙環,因此固定的CD137蛋白的脫除速率非常慢,並且報告的KD可能被高估了(圖10B)。圖10C顯示了BCY11863與Nectin-4結合,而CD137臂與固定在晶片上的CD137蛋白結合,形成三元複合物。圖10D顯示了BCY11863與CD137結合,而Nectin-4結合臂與固定在晶片上的Nectin-4蛋白結合,形成三元複合物。圖10E證明了固定在SPR晶片上的BCY13582結合人類CD137的能力。
12. BCY11863對Nectin-4及CD137的選擇性
Nectin-4旁系同源物篩選:透過用生物素標記它們並將它們固定在鏈黴親和素表面上,使用SPR評估BCY11863與Nectin-1(2880-N1,R&D系統)、Nectin-2(2229-N2,R&D系統)、Nectin-3(3064-N3,R&D系統)、類Nectin-1(3678-S4-050,R&D系統)、類Nectin-2(3519-S4-050,R&D系統)、
類Nectin-3(4290-S4-050,R&D系統)、類Nectin-4(4164-S4,R&D系統)及類Nectin-5(2530-CD-050,R&D系統)的結合力。BCY11863在濃度高達5000nM時未顯示與這些標靶的任何結合。
CD137旁系同源物篩選:使用SPR評估可溶性鏈黴親和素捕獲的BCY13582(生物素化的BCY11863)與可溶性TNF家族受體OX40及CD40的結合。BCY13582在濃度高達100nM時不與這些標靶結合。
Retrogenix微陣列篩選:Retrogenix的細胞微陣列技術用於篩選生物素化BCY11863(稱為BCY13582)的特定脫靶結合相互作用。
對測試胜肽與固定的、未轉染的HEK293細胞以及與過表達Nectin-4及CD137(TNFRSF9)的細胞結合量的研究表明,1μM的測試胜肽是適合的篩選濃度。在這些條件下,篩選測試胜肽與人類HEK293細胞的結合,分別表達5484個全長人類質膜蛋白及分泌蛋白。這揭示了9個主要命中,包括Nectin-4及CD137。
每次主要命中(primary hits)均與兩個控制組受體(TGFBR2及EGFR)一起重新表達,並在100μM BCY11863存在的情況下,用1μM BCY13582測試胜肽、1μM BCY13582測試胜肽重新測試,並進行其他陽性及陰性控制組治療(圖4)。除去非特異性、不可重現及非重要的命中後,測試胜肽仍然存在三種特異性相互作用。這些是Nectin-4及CD137(主要靶標)的不受束縛及束縛形式。
沒有針對BCY13582鑑定到特異性脫靶相互作用,表明其主要標靶具有高度特異性。
13. BCY11863在同型Nectin-4過表達的MC38腫瘤模型(MC38#13)中的抗腫瘤活性,每週兩次,劑量分別為在0、24小時給藥5mg/kg及在0小時給藥10mg
將6-8週齡的雌性C57BL/6J-hCD137小鼠[B-hTNFRSF9(CD137)小鼠;Biocytogen]皮下植入1x106 MC38#13(經過工程改造以過表達鼠Nectin-4的MC38細胞)細胞。當平均腫瘤體積達到約95mm3時,將小鼠隨機分為治療組(n=6/組),並用每週劑量的媒介物(25mM組胺酸,10%蔗糖,pH7)或10mg/kg BCY11863進行治療,其中在兩個給藥週期中有兩個不同的給藥時間表(D0及D7在0小時及24小時時給藥5mg/kg BCY11863,或D0及D7在0小時時為10mg/kg)。所有治療均靜脈內給藥(IV)。從治療開始直到第15天監測腫瘤的生長。
在兩種給藥方案中,BCY11863均具有顯著的抗腫瘤活性,但是當在治療開始後第15天分析了完整的反應時,在0小時及24小時給藥5mg/kg的劑量方案優於在0小時給藥10mg/kg的劑量方案(圖12)。D0及D7在0小時及24小時時給藥5mg/kg BCY11863導致6個完全腫瘤緩解中的4個,而D0及D7在0小時給藥10mg/kg BCY11863導致6個完全腫瘤緩解中的一個。這些數據與BCY11863小鼠血漿PK數據一起表明,將BCY11863血漿暴露量維持在每週週期0小時及24小時給藥5mg/kg產生的量可在MC38#13腫瘤模型中產生接近完全的抗腫瘤反應。
14. BCY11863在同型Nectin-4過表達的MC38腫瘤模型中的抗腫瘤活性(MC38#13)
以3、10及30mg/kg的每週3次劑量,以每週、每兩周及每天對皮下植入1x106 MC38#13(經過工程改造以過表達鼠Nectin-4的MC38細胞)細胞的6至8週齡雌性C57BL/6J-hCD137小鼠[B-hTNFRSF9(CD137)小鼠;Biocytogen]給藥。當平均腫瘤體積達到約107mm3時,將小鼠隨機分為治療組(n=6/組),並用21日日劑量的媒介物(25mM組胺酸,10%蔗糖,pH7)治療。BCY11863治療以三種不同的時間表(QD:每天;BIW:每週兩次或QW:每週)劃分為三種不同的總給藥劑量(每週總劑量分別為3、10及30mg/kg)進行。不同的BCY11863治療組每日接受21次劑量(0.43、1.4或4.3mg/kg),6次每週兩次的劑量(1.5、5或15mg/kg)或每週3次的劑量(3、10或30mg/kg)。所有治療均靜脈內給藥(IV)。監測腫瘤的生長直到腫瘤達到超過2000mm3的體積,或直到治療開始後31天。追蹤完全緩解者(沒有明顯腫瘤的動物)直到D52。
BCY11863導致顯著的抗腫瘤活性,許多給藥方案中BIW給藥方案是最有效的方案,特別是5mg/kg BIW劑量。這透過在第52天完全緩解動物的數量證明。治療開始後第52天,用BCY11863以BIW治療的15/18小鼠為完全緩解,用BCY11863以QD治療的12/18小鼠為完全緩解,而用BCY11863以QW治療的6/18小鼠為完全緩解。5mg/kg BIW劑量可實現6/6 CRs的100%的完全緩解率(complete response rate)(圖13)。這些數據與BCY11863小鼠血漿PK數據一起表明,在MC38#13腫瘤模型中,BCY11863的抗腫瘤反應無需連續的BCY11863血漿暴露。
<110> 英商拜西可泰克斯有限公司
<120> 異質雙環肽複合物
<130> BIC-C-P2832TW
<150> 62/880,191
<151> 2019-07-30
<150> 62/910,088
<151> 2019-10-03
<150> 62/931,442
<151> 2019-11-06
<150> 63/022,667
<151> 2020-05-11
<150> 63/024,715
<151> 2020-05-14
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 15
<212> PRT
<213> Artificial
<220>
<223> Synthetic Peptide
<220>
<221> Xaa
<222> (3)..(3)
<223> Xaa is 1Nal
<220>
<221> Xaa
<222> (7)..(7)
<223> Xaa is HArg
<220>
<221> Xaa
<222> (13)..(13)
<223> Xaa is HyP
<400> 1
<210> 2
<211> 16
<212> PRT
<213> Artificial
<220>
<223> Synthetic Peptide
<220>
<221> Xaa
<222> (2)..(2)
<223> Xaa is tBuAla
<220>
<221> Xaa
<222> (5)..(5)
<223> Xaa is D-Lys(PYA)
<220>
<221> Xaa
<222> (14)..(14)
<223> Xaa is Nle
<400> 2
<210> 3
<211> 16
<212> PRT
<213> Artificial
<220>
<223> Synthetic Peptide
<220>
<221> Xaa
<222> (2)..(2)
<223> Xaa is tBuAla
<220>
<221> Xaa
<222> (5)..(5)
<223> Xaa is D-Lys(PYA)
<220>
<221> Xaa
<222> (14)..(14)
<223> Xaa is Nle
<400> 3
<210> 4
<211> 16
<212> PRT
<213> Artificial
<220>
<223> Synthetic Peptide
<220>
<221> Xaa
<222> (2)..(2)
<223> Xaa is tBuAla
<220>
<221> Xaa
<222> (5)..(5)
<223> Xaa is D-Lys(PYA)
<220>
<221> Xaa
<222> (14)..(14)
<223> Xaa is Nle
<400> 4
Claims (6)
- 一種異質雙環肽複合物,包括:(a)一第一胜肽配體,與Nectin-4結合,且該第一胜肽配體具有序列CiP[1Nal][dD]CiiM[HArg]DWSTP[HyP]WCiii(SEQ ID NO:1;BCY8116);透過一N-(酸-PEG3)-N-雙(PEG3-疊氮化物)(N-(acid-PEG3)-N-bis(PEG3-azide))連接胜肽共軛至(b)兩個第二胜肽配體,與CD137結合,該第二胜肽配體具有序列Ac-Ci[tBuAla]PE[D-Lys(PYA)]PYCiiFADPY[Nle]Ciii-A(SEQ ID NO:2;BCY8928);其中每個該胜肽配體包括一多肽,該多肽包括被兩個循環序列隔開的三個反應性半胱胺酸基團(Ci、Cii及Ciii),及一分子支架,該分子支架為1,1’,1”-(1,3,5-三嗪烷-1,3,5-三基)三丙-2-烯-1-酮(1,1’,1”-(1,3,5-triazinane-1,3,5-triyl)triprop-2-en-1-one)(TATA),且該分子支架與該多肽的該反應性半胱胺酸基團形成共價鍵,從而在該分子支架上形成兩個多肽環;其中Ac代表乙醯基、HArg代表高精胺酸、HyP代表反式-4-羥基-L-脯胺酸、1Nal代表1-萘丙胺酸、tBuAla代表叔丁基丙胺酸、PYA代表4-戊炔酸及Nle代表正白胺酸。
- 如請求項1或2所述的異質雙環肽複合物,其中該藥學上可接受的鹽是選自該游離酸或該鈉鹽、該鉀鹽、該鈣鹽、該銨鹽。
- 一種醫藥組合物,包括請求項1至3中任一項所述的該異質雙環肽複合物與一或多種藥學上可接受的賦形劑合併使用。
- 如請求項1至3中任一項所述的異質雙環肽複合物,是用於預防、抑制或治療癌症之用途。
- 一種治療癌症的方法,包括:以一劑量頻率給予如請求項1至3中任一項所述的異質雙環肽複合物,而該劑量頻率為以不維持該複合物的血漿濃度高於該複合物的體外EC50的劑量頻率。
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962880191P | 2019-07-30 | 2019-07-30 | |
US62/880,191 | 2019-07-30 | ||
US201962910088P | 2019-10-03 | 2019-10-03 | |
US62/910,088 | 2019-10-03 | ||
US201962931442P | 2019-11-06 | 2019-11-06 | |
US62/931,442 | 2019-11-06 | ||
US202063022667P | 2020-05-11 | 2020-05-11 | |
US63/022,667 | 2020-05-11 | ||
US202063024715P | 2020-05-14 | 2020-05-14 | |
US63/024,715 | 2020-05-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202118770A true TW202118770A (zh) | 2021-05-16 |
Family
ID=71948620
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109124760A TW202110485A (zh) | 2019-07-30 | 2020-07-22 | 異質雙環肽複合物 |
TW109124761A TW202118770A (zh) | 2019-07-30 | 2020-07-22 | 異質雙環肽複合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW109124760A TW202110485A (zh) | 2019-07-30 | 2020-07-22 | 異質雙環肽複合物 |
Country Status (12)
Country | Link |
---|---|
US (6) | US11312749B2 (zh) |
EP (4) | EP4003530A1 (zh) |
JP (4) | JP2022544058A (zh) |
KR (3) | KR20220049529A (zh) |
CN (4) | CN114502598A (zh) |
AU (3) | AU2020323739A1 (zh) |
BR (3) | BR112022001521A2 (zh) |
CA (3) | CA3148039A1 (zh) |
IL (3) | IL290089A (zh) |
MX (3) | MX2022001290A (zh) |
TW (2) | TW202110485A (zh) |
WO (4) | WO2021019245A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
CN111183147A (zh) | 2017-08-04 | 2020-05-19 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
EP3755725A1 (en) | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
CN112236442A (zh) | 2018-04-04 | 2021-01-15 | 拜斯科技术开发有限公司 | 异源串联双环肽复合物 |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
CA3137095A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
JP2022551607A (ja) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
KR20230074721A (ko) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도 |
JP2024502189A (ja) * | 2021-01-11 | 2024-01-17 | バイシクルティーエクス・リミテッド | 癌を処置する方法 |
AU2022356942A1 (en) * | 2021-09-29 | 2024-05-09 | Conjustar (Zhuhai) Biologics Co., Ltd. | Tricyclic polypeptide conjugated drug and use thereof |
WO2023089308A1 (en) * | 2021-11-16 | 2023-05-25 | Bicycletx Limited | Methods for treating cancer |
CN116768978A (zh) * | 2022-03-11 | 2023-09-19 | 上海智肽生物科技有限公司 | Nectin-4靶向肽化合物及其药物偶联物 |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4709016A (en) | 1982-02-01 | 1987-11-24 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US5516931A (en) | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
US5650270A (en) | 1982-02-01 | 1997-07-22 | Northeastern University | Molecular analytical release tags and their use in chemical analysis |
US4650750A (en) | 1982-02-01 | 1987-03-17 | Giese Roger W | Method of chemical analysis employing molecular release tag compounds |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
US6326144B1 (en) | 1998-09-18 | 2001-12-04 | Massachusetts Institute Of Technology | Biological applications of quantum dots |
JP4630459B2 (ja) | 1998-09-24 | 2011-02-09 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | 水溶性発光量子ドットおよびその生体分子コンジュゲート |
US6927203B1 (en) * | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
JP4078074B2 (ja) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | ピロロ[2,3−d]ピリミジン化合物 |
DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
EP1487972B1 (en) | 2002-02-21 | 2015-08-12 | Institute Of Virology | Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use |
WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
SG160211A1 (en) | 2003-04-03 | 2010-04-29 | Semafore Pharmaceuticals Inc | Pi-3 kinase inhibitor prodrugs |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
CA2505655C (en) | 2004-04-28 | 2013-07-09 | Warren Chan | Stable, water-soluble quantum dot, method of preparation and conjugates thereof |
CN101031569B (zh) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮 |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
DK1844337T3 (da) | 2005-01-24 | 2013-09-30 | Pepscan Systems Bv | Bindingsforbindelser, immunogene forbindelser og peptidmimetika |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
CN103819416A (zh) | 2005-10-07 | 2014-05-28 | 埃克塞里艾克西斯公司 | N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途 |
WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl-substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
CN101472930B (zh) | 2006-04-26 | 2011-12-14 | 霍夫曼-拉罗奇有限公司 | 用作PI3K抑制剂的噻吩并[3,2-d]嘧啶的衍生物 |
MY150757A (en) | 2006-09-15 | 2014-02-28 | Siemens Medical Solutions | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
ES2557930T3 (es) | 2007-03-12 | 2016-01-29 | Ym Biosciences Australia Pty Ltd | Compuestos de fenilaminopirimidina y usos de los mismos |
PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
CA2690449A1 (en) | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Synergistic treatment of cells that express epha2 and erbb2 |
EP2474613B2 (en) | 2008-02-05 | 2022-02-16 | BicycleRD Limited | Methods and compositions |
ES2602577T3 (es) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Derivados de azetidina y ciclobutano como inhibidores de JAK |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
WO2012057624A1 (en) | 2010-10-25 | 2012-05-03 | Pepscan Systems B.V. | Novel bicyclic peptide mimetics |
LT3299377T (lt) | 2011-10-07 | 2021-03-25 | Bicyclerd Limited | Struktūrizuoto polipeptido specifiškumo moduliavimas |
GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
JP6548630B2 (ja) | 2013-03-12 | 2019-07-24 | モレキュラー テンプレーツ, インク.Molecular Templates, Inc. | 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素aサブユニット領域とを含む細胞毒性タンパク質 |
US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
GB201306623D0 (en) | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
WO2014190257A2 (en) | 2013-05-23 | 2014-11-27 | Ohio State Innovation Foundation | Chemical synthesis and screening of bicyclic peptide libraries |
ES2715379T3 (es) | 2013-10-28 | 2019-06-04 | Bicyclerd Ltd | Novedosos polipéptidos |
US11474101B2 (en) | 2014-05-08 | 2022-10-18 | Novodiax, Inc. | Direct immunohistochemistry assay |
PT3149025T (pt) | 2014-05-21 | 2019-08-01 | Entrada Therapeutics Inc | Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos |
CA2965754C (en) | 2014-10-29 | 2024-01-02 | Bicycle Therapeutics Limited | Bicyclic peptide ligands specific for mt1-mmp |
WO2016171242A1 (ja) | 2015-04-24 | 2016-10-27 | 第一三共株式会社 | Epha2の検出 |
CN107810190A (zh) | 2015-04-28 | 2018-03-16 | 洛桑联邦政府综合工科学校(Epfl) | 酶活化因子XII (FXIIa)的新型抑制剂 |
CN108883199A (zh) | 2016-03-16 | 2018-11-23 | 梅里麦克制药股份有限公司 | 肝配蛋白受体a2(epha2)的纳米脂质体靶向和相关诊断 |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
AU2017252233A1 (en) | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
US10441663B2 (en) | 2016-11-27 | 2019-10-15 | Bicyclerd Limited | Methods for treating cancer |
CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
CN110506049A (zh) | 2016-12-23 | 2019-11-26 | 拜斯科技术开发有限公司 | 用于结合mt1-mmp的肽配体 |
US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
GB201706477D0 (en) | 2017-04-24 | 2017-06-07 | Bicycle Therapeutics Ltd | Modification of polypeptides |
US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
CN111032678A (zh) | 2017-06-26 | 2020-04-17 | 拜西克尔德有限公司 | 具有可检测部分的双环肽配体和其用途 |
CN111183147A (zh) | 2017-08-04 | 2020-05-19 | 拜斯科技术开发有限公司 | Cd137特异性的双环肽配体 |
US20200291096A1 (en) | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
EP3668550A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
WO2019136442A1 (en) | 2018-01-08 | 2019-07-11 | Kleo Pharmaceuticals, Inc. | Cd16a binding agents and uses thereof |
EP3755725A1 (en) | 2018-02-23 | 2020-12-30 | BicycleTX Limited | Multimeric bicyclic peptide ligands |
CN112236442A (zh) | 2018-04-04 | 2021-01-15 | 拜斯科技术开发有限公司 | 异源串联双环肽复合物 |
EP3797120A1 (en) | 2018-05-21 | 2021-03-31 | Compass Therapeutics LLC | Compositions and methods for enhancing the killing of target cells by nk cells |
US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
GB201810325D0 (en) | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to PSMA |
WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
US20220024982A1 (en) | 2018-12-13 | 2022-01-27 | Bicycletx Limited | Bicyclic peptide ligands specific for mt1-mmp |
KR20210105890A (ko) | 2018-12-17 | 2021-08-27 | 레비토프 리미티드 | 트윈 면역 세포 인게이저 |
WO2020128526A1 (en) | 2018-12-21 | 2020-06-25 | Bicycletx Limited | Bicyclic peptide ligands specific for pd-l1 |
EP3897850A1 (en) | 2018-12-21 | 2021-10-27 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
WO2020201753A1 (en) | 2019-04-02 | 2020-10-08 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
CA3137095A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
US20220275053A1 (en) | 2019-08-13 | 2022-09-01 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
JP2022551607A (ja) | 2019-10-03 | 2022-12-12 | バイスクルテクス・リミテッド | ヘテロタンデム二環式ペプチド複合体 |
CN114760988A (zh) | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
KR20230065231A (ko) | 2020-06-12 | 2023-05-11 | 바이사이클티엑스 리미티드 | 에리트로포이에틴-생성시키는 간세포 수용체 a2 (epha2)의 과다발현을 특징으로 하는 질환의 치료 |
KR20230074721A (ko) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도 |
AU2022206577A1 (en) | 2021-01-08 | 2023-08-24 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
JP2024502189A (ja) | 2021-01-11 | 2024-01-17 | バイシクルティーエクス・リミテッド | 癌を処置する方法 |
-
2020
- 2020-07-22 TW TW109124760A patent/TW202110485A/zh unknown
- 2020-07-22 TW TW109124761A patent/TW202118770A/zh unknown
- 2020-07-29 US US16/941,588 patent/US11312749B2/en active Active
- 2020-07-29 US US16/941,614 patent/US11306123B2/en active Active
- 2020-07-30 CN CN202080066107.XA patent/CN114502598A/zh active Pending
- 2020-07-30 CN CN202080060998.8A patent/CN114521197A/zh active Pending
- 2020-07-30 US US17/630,747 patent/US20230129258A1/en active Pending
- 2020-07-30 MX MX2022001290A patent/MX2022001290A/es unknown
- 2020-07-30 AU AU2020323739A patent/AU2020323739A1/en active Pending
- 2020-07-30 MX MX2022001288A patent/MX2022001288A/es unknown
- 2020-07-30 JP JP2022506048A patent/JP2022544058A/ja active Pending
- 2020-07-30 AU AU2020319704A patent/AU2020319704A1/en active Pending
- 2020-07-30 JP JP2022505570A patent/JP2022542286A/ja active Pending
- 2020-07-30 CN CN202080059317.6A patent/CN114555626A/zh active Pending
- 2020-07-30 CN CN202080053807.5A patent/CN114341190A/zh active Pending
- 2020-07-30 EP EP20751644.4A patent/EP4003530A1/en active Pending
- 2020-07-30 EP EP20751642.8A patent/EP4003529A1/en active Pending
- 2020-07-30 BR BR112022001521A patent/BR112022001521A2/pt unknown
- 2020-07-30 US US17/630,314 patent/US20220257784A1/en active Pending
- 2020-07-30 EP EP20751264.1A patent/EP4003527A1/en active Pending
- 2020-07-30 CA CA3148039A patent/CA3148039A1/en active Pending
- 2020-07-30 CA CA3147570A patent/CA3147570A1/en active Pending
- 2020-07-30 WO PCT/GB2020/051829 patent/WO2021019245A1/en unknown
- 2020-07-30 KR KR1020227006633A patent/KR20220049529A/ko unknown
- 2020-07-30 CA CA3148033A patent/CA3148033A1/en active Pending
- 2020-07-30 BR BR112022001532A patent/BR112022001532A2/pt unknown
- 2020-07-30 WO PCT/GB2020/051827 patent/WO2021019243A1/en active Application Filing
- 2020-07-30 BR BR112022001520A patent/BR112022001520A2/pt unknown
- 2020-07-30 EP EP20751265.8A patent/EP4003528A1/en active Pending
- 2020-07-30 WO PCT/GB2020/051828 patent/WO2021019244A1/en active Application Filing
- 2020-07-30 JP JP2022505581A patent/JP2022542291A/ja active Pending
- 2020-07-30 WO PCT/GB2020/051831 patent/WO2021019246A1/en unknown
- 2020-07-30 JP JP2022506077A patent/JP2022542386A/ja active Pending
- 2020-07-30 KR KR1020227006616A patent/KR20220051345A/ko active Search and Examination
- 2020-07-30 KR KR1020227006669A patent/KR20220054309A/ko unknown
- 2020-07-30 AU AU2020322193A patent/AU2020322193A1/en active Pending
- 2020-07-30 MX MX2022001273A patent/MX2022001273A/es unknown
-
2022
- 2022-01-24 IL IL290089A patent/IL290089A/en unknown
- 2022-01-24 IL IL290090A patent/IL290090A/en unknown
- 2022-01-24 IL IL290093A patent/IL290093A/en unknown
- 2022-02-02 US US17/590,875 patent/US20220227811A1/en active Pending
- 2022-02-04 US US17/592,966 patent/US11970553B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202118770A (zh) | 異質雙環肽複合物 | |
US20220213145A1 (en) | Bicyclic peptide ligands specific for cd137 | |
JP2024023291A (ja) | 多量体二環式ペプチドリガンド | |
JP2024062998A (ja) | ヘテロタンデム二環式ペプチド複合体 | |
CN111741771A (zh) | 特异于epha2的双环肽配体 | |
JP2022514618A (ja) | Pd-l1に特異的な二環式ペプチドリガンド | |
CN114787197A (zh) | 修饰的多聚双环肽配体 | |
CN113474046A (zh) | Il-17特异性的双环肽配体 | |
CN113260420A (zh) | Pd-l1特异性的双环肽配体 | |
CN113507960A (zh) | Psma特异性的双环肽配体 | |
CN112533937A (zh) | 用于结合cd38的肽配体 | |
CN113597317A (zh) | Cd38特异性的双环肽配体 | |
CN113543813B (zh) | Cd38特异性的双环肽配体 | |
EA046193B1 (ru) | Гетеротандемный бициклический пептидный комплекс |